Latest / Behind the Bastards / Part Two: Peter Attia and the Cult of Longevity
Transcript
- 0:05Speaker 1: Welcome back to Behind the Bastards, a podcast about the
- 0:08Speaker 1: very worst people in all of history. And here to
- 0:12Speaker 1: talk about, well, here to do a special reverse bastards
- 0:15Speaker 1: episode where I don't have to research and write about
- 0:19Speaker 1: a terrible person. My guest does is Dr. Kaveh Hoda,
- 0:22Speaker 1: who has been very kindly teaching us about Dr.
- 0:26Speaker 2: Peter Attia. Yeah. Atiyah? I don't know, actually. It's a
- 0:29Speaker 2: good question. Atiyah.
- 0:31Speaker 3: Atiyah.
- 0:31Speaker 1: Sorry.
- 0:31Speaker 2: Peter Atiyah. Peter, I apologize.
- 0:33Speaker 4: I know that.
- 0:33Speaker 1: You said that correctly. I got it wrong, because my
- 0:36Speaker 1: brain does not hold pronunciations well.
- 0:38Speaker 2: I might be wrong. Listen, I don't know if I'm
- 0:41Speaker 2: saying my own name right, so I can't be certain
- 0:45Speaker 2: about anyone else. So sorry, Peter, if that's the case.
- 0:49Speaker 1: Who's to say?
- 0:57Speaker 2: Okay. You guys ready to get back into this?
- 0:59Speaker 4: Yeah, yeah, yeah.
- 0:59Speaker 1: Let's do it.
- 1:00Speaker 3: Okay.
- 1:01Speaker 2: When we left off, our hero, Peter Attia, had left
- 1:05Speaker 2: the oppressive groupthink of medical training.
- 1:10Speaker 1: Finally.
- 1:10Speaker 2: It was finally. It was only a matter of time.
- 1:13Speaker 2: He was pretty upset about not being appreciated for attempting
- 1:17Speaker 2: to operate outside the Johns Hopkins protocols. Being a maverick.
- 1:23Speaker 2: A renegade. Yeah. He doesn't play by the rules, but
- 1:26Speaker 2: he gets results. Yeah. You want a rebel doctor.
- 1:29Speaker 1: That's what you want. That's right. I love it when
- 1:31Speaker 1: my doctors are rebel.
- 1:33Speaker 2: That's really outside the box.
- 1:35Speaker 5: Yeah.
- 1:35Speaker 2: Getting weird with medicine. Yeah.
- 1:37Speaker 1: That's what you want. A lot of people say smearing
- 1:38Speaker 1: poop into an open wound is bad for you, but
- 1:41Speaker 1: they're just sheep. I like to get away from the herd.
- 1:44Speaker 1: I like to try new things.
- 1:45Speaker 2: Yeah. Get that in there real good. Can we stop this?
- 1:49Speaker 5: Yep.
- 1:49Speaker 1: Nothing's bolder than sepsis i i don't get.
- 1:52Speaker 3: I don't get paid enough for this shit can we that.
- 1:55Speaker 2: Yeah well i mean if you didn't stop me i
- 1:57Speaker 2: might have gotten stuck in that yeah it is it
- 2:00Speaker 2: is disturbing how easily my brain can just like in
- 2:04Speaker 2: like get into that role of the manosphere dude and
- 2:08Speaker 2: that is it's easy it's funny to work on the
- 2:11Speaker 2: joke about yeah Yeah.
- 2:13Speaker 1: But back to Petar.
- 2:15Speaker 2: So let's get back to him. So he decides to join,
- 2:18Speaker 2: leaving the residency, decides to join a consulting firm called
- 2:21Speaker 2: McKinsey and Company. Oh, good.
- 2:24Speaker 1: Oh, I'm glad they're showing up. That's fun.
- 2:26Speaker 2: Yeah. Yeah, I was going to ask. Real peak McKinsey years.
- 2:29Speaker 1: Yeah.
- 2:30Speaker 2: Yeah. Okay.
- 2:31Speaker 1: They're one of those like bloodless consultants. Sorry, you're going
- 2:33Speaker 1: to talk about them. Yeah, yeah, yeah. No, no, no.
- 2:34Speaker 2: Please, please, please.
- 2:35Speaker 1: They're one of those like consulting firms who you bring
- 2:38Speaker 1: in to tell like, here's how many people you should
- 2:40Speaker 1: fire to maximize shareholder value and the like, right?
- 2:43Speaker 2: That is correct. They are a global management consulting firm
- 2:48Speaker 2: that advises major corporations, governments, both here and abroad, and
- 2:54Speaker 2: institutions on strategy operations some.
- 2:57Speaker 1: People call them bloodless ghouls but right no i don't
- 3:01Speaker 1: because i i support actually the bloodless ghoul community you
- 3:04Speaker 1: are valid you are beautiful and i love you bloodless.
- 3:08Speaker 2: You are seen they are one of the most influential
- 3:13Speaker 2: oldest and maybe controversial consulting firms in the world let's
- 3:17Speaker 2: talk about them because he decided to go work for
- 3:19Speaker 2: them and i think that says something about a person
- 3:21Speaker 2: good sign So they're firm with the history of being
- 3:25Speaker 2: criticized for a lot of things, including involvement with the
- 3:30Speaker 2: opioid crisis. Have you heard of the opioid crisis?
- 3:32Speaker 3: I have.
- 3:33Speaker 1: Oh, man. Yeah. I've had a few myself.
- 3:37Speaker 2: Robert.
- 3:38Speaker 3: Robert.
- 3:38Speaker 4: It's a bit.
- 3:39Speaker 1: It's a bit.
- 3:39Speaker 2: It's a bit. Please say it's a bit.
- 3:41Speaker 1: It's a bit. I'm a medical doctor.
- 3:43Speaker 2: I'm a professional.
- 3:44Speaker 1: I only do opiates in Mexico. And now I don't
- 3:48Speaker 1: do opiates in Mexico anymore because of fucking fentanyl. Man,
- 3:50Speaker 1: it ruins so much. You used to be able to
- 3:52Speaker 1: just buy opiates off of a pharmacy in Guatemala or
- 3:55Speaker 1: something and know that they were just hydrocodone. You could
- 3:58Speaker 1: pick it up at the grocery store. It was beautiful. Anyway, whatever.
- 4:03Speaker 2: So McKinsey- and company, both of them, were hired by
- 4:07Speaker 2: Purdue Pharma to work on strategies to increase opioid sales
- 4:11Speaker 2: because they just weren't selling enough.
- 4:14Speaker 1: Yeah, 2006 is like peak getting Americans addicted to painkillers years.
- 4:19Speaker 2: That's exactly what we're talking about here.
- 4:22Speaker 1: Yeah.
- 4:22Speaker 2: Oh, cool. They provided them service for over 15 years,
- 4:27Speaker 2: specifically advising them on marketing and sales strategies to aggressively
- 4:33Speaker 2: increase the revenue of of OxyContin, the opioid painkiller.
- 4:37Speaker 1: You want to aggressively increase people using Oxy, yeah.
- 4:41Speaker 2: That's what they did. So they advised Purdue, really focusing
- 4:46Speaker 2: their sales representative visits on doctors who were already writing
- 4:51Speaker 2: high volumes of prescriptions. And according to the New York
- 4:55Speaker 2: Times in 2013, McKinsey designed a specific strategy to turbocharge
- 5:02Speaker 2: OxyContin sales And they advised the Sackler family, the people
- 5:07Speaker 2: who own Purdue, to push the higher dose pills. They
- 5:10Speaker 2: did a lot of really fun stuff. Because of this,
- 5:14Speaker 2: they faced a lot of legal challenges and some setbacks
- 5:18Speaker 2: for the company. They've had to cut back at least 10%
- 5:20Speaker 2: of their global workforce. They had to pay nearly $ 600
- 5:25Speaker 2: million American dollars to settle investigations.
- 5:28Speaker 5: Yeah.
- 5:28Speaker 1: A fucking pittance, honestly. But yeah.
- 5:31Speaker 2: Probably.
- 5:31Speaker 1: Yeah.
- 5:32Speaker 2: And by these investigations brought on by 49 different American states.
- 5:36Speaker 2: I'm not sure which state didn't, actually. I wish I
- 5:39Speaker 2: had looked that up because I'm betting it's Alaska, but
- 5:41Speaker 2: I don't know. And the DOJ announced a settlement resolving
- 5:46Speaker 2: civil and criminal probes with McKinsey accepting responsibility for a
- 5:51Speaker 2: misdemeanor charge of conspiring to aid and abet the misbranding
- 5:58Speaker 2: of prescription drugs. So they also had a senior partner,
- 6:02Speaker 2: Martin Elling, who faced felony obstruction of justice charges for
- 6:06Speaker 2: intentionally deleting Purdue. And they had to pay also 125
- 6:10Speaker 2: million into the Purdue Pharmacy bankruptcy estate to fund treatment programs.
- 6:14Speaker 2: But what I have here is I printed out, I
- 6:17Speaker 2: went to the Department of Justice, the Office of Public Affairs.
- 6:22Speaker 2: And I printed out there some interesting stuff that they posted.
- 6:27Speaker 2: about these court hearings. So they leveled a couple of
- 6:32Speaker 2: complaints against the Perdue family, and they leveled a number
- 6:37Speaker 2: against McKinsey.
- 6:39Speaker 1: The Sackler family, yeah.
- 6:40Speaker 2: Sackler family, sorry. And two of the ones they leveled,
- 6:44Speaker 2: two of the charges they leveled were criminal misbranding and
- 6:48Speaker 2: false claims to the FDA. So this is fun. So
- 6:52Speaker 2: the DOJ, this is a quote from the Office of
- 6:55Speaker 2: Public Affairs, the Department of Justice, Quote, the DOJ leveled
- 6:59Speaker 2: a criminal misbranding charge against McKinsey for falsely marketing it
- 7:03Speaker 2: as less addictive, less subject to abuse and diversion, and
- 7:07Speaker 2: less likely to cause dependence and withdrawal than other pain medications.
- 7:11Speaker 2: This was specifically their recommendations that McKinsey made to Purdue.
- 7:17Speaker 2: They were like, they worked on messaging. They're like, hey,
- 7:19Speaker 2: we have to counter these emotional public health warnings. including
- 7:23Speaker 2: these complaints that mothers had of teenagers that had overdosed.
- 7:26Speaker 2: And so they had this whole marketing campaign to fight that.
- 7:32Speaker 2: Among other strategies, intensifying marketing to high-value prescribers, including prescribers
- 7:38Speaker 2: who were writing opioid prescriptions for uses that were unsafe, ineffective,
- 7:42Speaker 2: and medically unnecessary. So what McKinsey did, basically let me
- 7:45Speaker 2: translate some of that, was like, hey. Yeah. These people
- 7:49Speaker 2: who are writing the worst prescriptions, the most questionable prescriptions,
- 7:54Speaker 2: let's really drill down on them and get them to
- 7:57Speaker 2: write even more. Hit them up. That should be number one.
- 8:02Speaker 2: Don't go to the person that you have to convince.
- 8:05Speaker 2: Go to the person that's just doing it and just
- 8:08Speaker 2: work on them the whole time.
- 8:11Speaker 1: Makes sense.
- 8:13Speaker 2: McKinsey consultants spoke with Purdue about the concerns and increasing
- 8:17Speaker 2: reluctance of pharmacists and pharmacy chains to fill prescriptions for
- 8:21Speaker 2: OxyContin as abuse of the drug rose. McKinsey consultants also
- 8:26Speaker 2: went on several ride-alongs with Purdue sales representatives in the
- 8:30Speaker 2: field as these sales representatives called on prescribers and pharmacists.
- 8:36Speaker 2: In notes about one of the ride-alongs, a McKinsey consultant wrote, quote,
- 8:41Speaker 2: pharmacist had a gun and was shaking abuse is definitely
- 8:45Speaker 2: a huge issue they just kept doing it they set
- 8:51Speaker 2: them on ride-alongs to convince them to work harder.
- 8:54Speaker 1: It's insane that's nuts.
- 8:56Speaker 2: And then on top of that they also got uh
- 9:00Speaker 2: leveled uh for claims against the fda and McKinsey U.S.
- 9:05Speaker 2: knowingly misled the FDA by assigning consultants to concurrently work
- 9:09Speaker 2: on both FDA projects and competitively sensitive Purdue projects. So
- 9:15Speaker 2: basically what they did was they said to the FDA, hey,
- 9:17Speaker 2: we're going to give you some of our consultants. They're
- 9:19Speaker 2: going to help you with managing this opioid crisis. And
- 9:22Speaker 2: it was the same consultants that were working on Purdue.
- 9:25Speaker 2: Who had helped make it worse.
- 9:26Speaker 1: Yeah. These guys really know the opioid crisis because they
- 9:31Speaker 1: helped cause it. But they're experts.
- 9:33Speaker 2: Yeah. Yeah.
- 9:34Speaker 1: It would be like bringing in a bunch of former
- 9:36Speaker 1: SS guys as experts on denazification.
- 9:38Speaker 5: It's like, look, they know who the Nazis were, obviously.
- 9:40Speaker 5: They know what they're talking about. They know what they're
- 9:43Speaker 5: talking about. There's also criticism of their work with Enron,
- 9:48Speaker 5: as well as their work with China and Saudi Arabia
- 9:51Speaker 5: and their efforts to enable authoritarian regimes.
- 9:53Speaker 2: In those places. I'll leave that for James and Mia
- 9:59Speaker 2: to discuss it. that's probably more their wheelhouse. But they've
- 10:03Speaker 2: done worse things also in other places as well. Now,
- 10:08Speaker 2: Atiyah's work did not seem to be related to anything medical.
- 10:11Speaker 2: So I have to say, even though he was there
- 10:14Speaker 2: during the opioid crisis, it doesn't seem like he was
- 10:18Speaker 2: a part of it. He was focused on corporate risk,
- 10:22Speaker 2: and he worked as a management consultant during this time.
- 10:26Speaker 2: He considers this his recalibration phase, where he's exposed to
- 10:30Speaker 2: systems-level thinking. I don't know who he was working with,
- 10:34Speaker 2: but clearly it signals he has an interest in working
- 10:37Speaker 2: with affluent, optimization-oriented populations. Right. His core audience is high-income,
- 10:45Speaker 2: like high-income health-maxing professionals. People with the ability to pay
- 10:49Speaker 2: top dollar for the health. And I'm sure this is
- 10:51Speaker 2: a big part of why he ended up there. So
- 10:53Speaker 2: he's there for two years. And it kind of correlates
- 10:57Speaker 2: when the first major actions are taken against Perdue. So
- 11:01Speaker 2: I don't know if that was a part of why
- 11:02Speaker 2: he left or not. But he leaves after a couple years.
- 11:06Speaker 2: I think that's common for people doing the consultant gigs.
- 11:10Speaker 1: Yeah, yeah, yeah.
- 11:11Speaker 2: Right? And for reasons I'm not clear about, he's drawn
- 11:14Speaker 2: back to medicine. He gets very busy. He starts doing presentations,
- 11:20Speaker 2: lots of media stuff, doing TED Talks. He talks about
- 11:24Speaker 2: metabolic dysfunction a lot. He co-founds a startup called the
- 11:29Speaker 2: Nutrition Science Initiative, or NUSAI.
- 11:32Speaker 1: Yeah.
- 11:33Speaker 2: Gives him a very public-facing scientific role, and one that
- 11:36Speaker 2: he does without needing board certification.
- 11:40Speaker 1: Oh, that's handy.
- 11:41Speaker 2: That's great, right? His blog helps establish him as a
- 11:45Speaker 2: bit of a contrarian and... but one that can actually
- 11:49Speaker 2: discuss data. Sophie knows my thoughts about medical contrarians. It's
- 11:54Speaker 2: not great. And this is where the Atea content machine
- 11:58Speaker 2: really starts. These long form technical pieces framed as this
- 12:05Speaker 2: is what your doctor won't tell you. Again, has that real,
- 12:08Speaker 2: the one secret your doctors won't tell you energy. And
- 12:11Speaker 2: the rise of these doctors, these contrarian doctors, is something
- 12:15Speaker 2: that is very much a sore spot for me. Yeah.
- 12:18Speaker 2: And not that medicine's perfect, it's not. I'm not going
- 12:21Speaker 2: to say that it is. But a lot of these folks,
- 12:24Speaker 2: him included, did a lot of what is called, or
- 12:27Speaker 2: I call, I don't know if this is a term,
- 12:28Speaker 2: I'm sure it is, science washing. Like taking some of
- 12:32Speaker 2: the more blatantly crazy quack people, making them seem more legitimate,
- 12:38Speaker 2: and making the more blatantly anti-vax doctors seem a little
- 12:41Speaker 2: bit more legitimate, really paves the way for for the
- 12:45Speaker 2: Maha movement and where we are currently, again, in our
- 12:49Speaker 2: golden age of diarrhea. Now, eventually, in 2014, he starts
- 12:56Speaker 2: his own private longevity clinic, Early Medicine. And this is
- 13:01Speaker 2: really the scaffolding on which his whole shtick is built.
- 13:05Speaker 1: On moving forward. Yeah, yeah, yeah, yeah.
- 13:09Speaker 2: It allows him to operationalize the Med 3.0 framework that
- 13:13Speaker 2: he loves talking about.
- 13:15Speaker 1: I feel like you can see a hint of this
- 13:16Speaker 1: in the fact that he got so into nutrition, because
- 13:18Speaker 1: obviously nutrition is massively important for health, but also when
- 13:22Speaker 1: you're in the business of nutrition, because of the way
- 13:26Speaker 1: supplements and stuff are regulated, it means that you can,
- 13:30Speaker 1: I'm not saying he was, but you can be in
- 13:32Speaker 1: the business of just selling people nonsense and claiming it's
- 13:35Speaker 1: basically medicine, as long as you avoid certain phrasing, right?
- 13:39Speaker 1: That's exactly right. Anytime I hear nutrition, my warning bells
- 13:42Speaker 1: start going off, like when it's in the context of
- 13:46Speaker 1: a medical professional.
- 13:48Speaker 2: Absolutely true. It's really the Wild West, because being a
- 13:51Speaker 2: nutritionist could mean you have like two to three PhDs
- 13:55Speaker 2: in the matter or can mean you're a wellness influencer online.
- 14:00Speaker 2: And there's really a wide breadth of the conversation between
- 14:04Speaker 2: the two. So yeah, absolutely true. So during this time,
- 14:09Speaker 2: as he's creating this clinic, things he's doing are things
- 14:13Speaker 2: like continuous glucose monitors for non-diabetic patients, which you may
- 14:18Speaker 2: have already gathered from the way I said it is
- 14:20Speaker 2: not appropriate. repeated advanced lipid testing, VO2 max labs, routine
- 14:26Speaker 2: MRI scans, DEXA scans, is giving people expensive wearables, using
- 14:33Speaker 2: off-label drugs, doing after-hours consults. His clienteles are elite. They
- 14:39Speaker 2: want high-touch care. They aren't taking new clients, by the way,
- 14:42Speaker 2: I checked. It's a years-long wait list to get in.
- 14:46Speaker 2: And although it's not disclosed exactly how much, From the
- 14:50Speaker 2: accounts I've seen, he charges anywhere from $ 100, 000 to $ 500, 000
- 14:55Speaker 2: annually for this care in this clinic.
- 14:59Speaker 1: Nice work if you can get it.
- 15:00Speaker 2: Jesus. I mean, if I could find three people to
- 15:04Speaker 2: do that. Yeah, yeah.
- 15:06Speaker 1: I'll give you nutrition advice for half a million dollars
- 15:08Speaker 1: a year. Anyone listening, you know, wire the money ahead
- 15:11Speaker 1: of time, and I'll give you all the advice you
- 15:12Speaker 1: fucking want.
- 15:14Speaker 2: Will you be on call, though? Will you be on
- 15:16Speaker 2: call all the time? Sure.
- 15:18Speaker 1: You can call me.
- 15:20Speaker 2: I may not answer.
- 15:21Speaker 1: Eat more fiber. I don't know, man. Fuck it.
- 15:25Speaker 2: Hey, you're hired. You're in. Well done, buddy.
- 15:29Speaker 1: Could be worse.
- 15:30Speaker 2: If I start a concierge clinic, I am going to
- 15:32Speaker 2: hire you in a minute. Anyways, I could see why
- 15:35Speaker 2: it's so appealing. I will say this, though, as an aside,
- 15:39Speaker 2: I can only imagine as a doctor how annoying it
- 15:44Speaker 2: would be to be a regular doctor of one of
- 15:47Speaker 2: these patients once they leave this concierge clinic, and you
- 15:52Speaker 2: have to see them. Like the stuff they would expect,
- 15:55Speaker 2: it would just be wild. And I would not be
- 15:57Speaker 2: giving them. But like, they'd be like, my last doctor,
- 16:00Speaker 2: he did this and this, and he ordered this and
- 16:02Speaker 2: this and this, and he did this for me. And
- 16:03Speaker 2: I'd be like, no, I'm sorry. That's just, none of
- 16:06Speaker 2: that's appropriate or reasonable to do. And it would be
- 16:09Speaker 2: so painful. And of course, none of this is accessible
- 16:13Speaker 2: to the average patient, or I'm sure you can guess,
- 16:17Speaker 2: covered by insurance.
- 16:19Speaker 1: Yeah.
- 16:19Speaker 2: People like Atiyah or tech weirdo, Brian Johnson, other longevity enthusiasts.
- 16:26Speaker 2: They're famous. That guy, that's the guy with the sons
- 16:29Speaker 2: is blood boy for you listeners out there. Yeah.
- 16:31Speaker 1: Yeah.
- 16:31Speaker 4: Yeah.
- 16:32Speaker 1: And tracks his erections. Don't forget about that. Really loves
- 16:36Speaker 1: bragging about his four hour erections at night when he's sleeping.
- 16:40Speaker 2: Yeah.
- 16:40Speaker 3: Yeah.
- 16:40Speaker 2: Yeah.
- 16:40Speaker 1: Cool, man.
- 16:41Speaker 2: Great episode on him. And it was troubling. Um, lots
- 16:44Speaker 2: of weird tweets about his, um, girlfriend's vagina um yeah
- 16:50Speaker 2: and his and his son's erection just real weird real
- 16:53Speaker 2: weird stuff.
- 16:54Speaker 3: Really uh tmi my guy.
- 16:57Speaker 2: Yeah yeah and i'm not a person who says that
- 17:00Speaker 2: like i don't think i've ever said tmi before but
- 17:02Speaker 2: i think if i were to use it it would
- 17:04Speaker 2: be in this case tmi so uh these people the
- 17:08Speaker 2: reason i bring them up both him and natia would
- 17:10Speaker 2: would have you believe that this is all proof of
- 17:13Speaker 2: concept stuff And that, yeah, only rich people have it
- 17:17Speaker 2: for now, but eventually everyone's going to have it. But,
- 17:21Speaker 2: I mean, that's just not true. It's not scalable. These
- 17:25Speaker 2: longevity wellness people are essentially creating a two-tiered medical system
- 17:30Speaker 2: with a different level for the wealthy. I mean, you
- 17:33Speaker 2: could argue we already kind of have one, but that
- 17:35Speaker 2: gap will only grow. Right. Of course, like all bad people,
- 17:41Speaker 2: he starts a podcast. It's called The Drive in 2018.
- 17:46Speaker 2: They cover a range of topics built around his practice
- 17:51Speaker 2: and early medicine framework. He's really starting to build this
- 17:55Speaker 2: parasocial relationship with a high-value audience during this time. He's
- 18:00Speaker 2: making appearances on Oprah at least three times on the
- 18:03Speaker 2: Joe Rogan Experience. He's hanging out with Bill Ackman, Hugh Jackman. Oh, boy. Yeah.
- 18:10Speaker 1: A lot of Ackmans in there.
- 18:11Speaker 2: A lot of Ackman and Jackmans.
- 18:13Speaker 1: Yeah.
- 18:14Speaker 2: And Gwyneth Paltrow and other New York elites. Sure. His book, Outlive,
- 18:18Speaker 2: comes out in 2023 and shortly afterwards becomes a number
- 18:22Speaker 2: one bestseller.
- 18:24Speaker 1: Yeah, they love titles like that. I can see why
- 18:26Speaker 1: that one sold.
- 18:27Speaker 2: Really a good one, right?
- 18:28Speaker 1: Yeah, yeah.
- 18:29Speaker 2: Over 3 million copies and spent 131 weeks on the
- 18:34Speaker 2: New York Times non-fiction bestseller list. It's crazy.
- 18:39Speaker 1: That's bleak.
- 18:40Speaker 2: It's not great. He becomes a major figure in the
- 18:44Speaker 2: health and wellness scene. Millions of people tuning in to
- 18:47Speaker 2: what he has to say or write. And I am
- 18:50Speaker 2: a little, I don't want to get too far into
- 18:52Speaker 2: the medical minutia here, but I think it's kind of
- 18:55Speaker 2: important to do. And your audience is very smart. And
- 18:58Speaker 2: I'm not just saying that because I'm pandering, although I'm
- 19:01Speaker 2: clearly pandering. They are very intelligent. I think they can
- 19:03Speaker 2: hang with this. So I'm going to dig in a
- 19:06Speaker 2: little bit to the medical advice he's endorsing and why
- 19:10Speaker 2: it matters. Okay. He's moving past the lifespan stuff. He's
- 19:14Speaker 2: now about healthspan, the good years. Again, we are mind
- 19:17Speaker 2: and body sharp. I'm into that. I like that. And
- 19:20Speaker 2: this medicine 3.0, which his clients are paying top dollar for,
- 19:25Speaker 2: and he would describe as preventive, personalized, and data-driven approaches
- 19:29Speaker 2: to healthcare that focuses on avoiding disease rather than treating it,
- 19:34Speaker 2: treating disease. And what's, you know, by the way, um,
- 19:41Speaker 2: I get called a shill a lot for being part
- 19:44Speaker 2: of big pharma. And it's a lot of the same
- 19:46Speaker 2: people who are like, you only want these diseases. to
- 19:50Speaker 2: happen so you can be paid by pharma to treat them.
- 19:53Speaker 2: And I'm like, what do you think he's doing in
- 19:56Speaker 2: these situations? You think that these medicines he's giving you
- 19:59Speaker 2: are free? Anyway, sorry. A key part of his justification
- 20:05Speaker 2: for aggressive preventative treatments and aggressive pharmacology is this assertion
- 20:11Speaker 2: that he has that 90% of the U.S. population has
- 20:15Speaker 2: at least one of five markers of metabolic syndrome. Have
- 20:19Speaker 2: you guys heard of metabolic syndrome?
- 20:21Speaker 3: Yeah.
- 20:22Speaker 2: Is that real? It's real.
- 20:25Speaker 4: Okay, that's good.
- 20:25Speaker 2: It's real, but it is vague, so you are right
- 20:27Speaker 2: to be like, yeah, is it real?
- 20:29Speaker 1: I hear a lot of things called signs of metabolic
- 20:32Speaker 1: syndrome that just sound... Okay, so Cheryl, listen to you.
- 20:34Speaker 3: It's like, you know, a number of things that make
- 20:38Speaker 3: you at risk for other things. Am I in the
- 20:41Speaker 3: right space?
- 20:41Speaker 1: It just crops up a lot in grifty kind of
- 20:43Speaker 1: medical spaces.
- 20:43Speaker 3: Like, all these things means you might have a stroke,
- 20:46Speaker 3: or all these things means you might get type 2 diabetes,
- 20:50Speaker 3: or all these... Am I in the right... Is that correct,
- 20:53Speaker 3: my friend? You guys.
- 20:54Speaker 2: You guys are so smart. I'm not just saying that. Honestly.
- 20:56Speaker 1: I mean, I had a lot less specifics than she did,
- 20:58Speaker 1: but sure.
- 20:59Speaker 2: Yeah, that was good. But I meant you guys. I
- 21:01Speaker 2: meant her. This is really smart. I just don't want
- 21:04Speaker 2: you to feel bad. That is correct. Metabolic syndrome is
- 21:08Speaker 2: a real thing, although you're right to be kind of
- 21:11Speaker 2: questioning it because it's used by people both professionally who
- 21:15Speaker 2: know what they're talking about and by grifters to sell
- 21:19Speaker 2: you an enema made out of coffee. So you're right
- 21:24Speaker 2: to be concerned about it. Now, what it is, let's
- 21:25Speaker 2: go through it here, okay? Metabolic syndrome is important, and
- 21:29Speaker 2: we should touch base on what these five markers of
- 21:31Speaker 2: metabolic syndrome are. One, central or abdominal obesity, basically a
- 21:37Speaker 2: waist circumference greater than or equal to 102 centimeters in men,
- 21:41Speaker 2: 88 centimeters in women, just a big gut. You get
- 21:44Speaker 2: adipose tissue in your gut. It changes the way your
- 21:47Speaker 2: body acts with insulin. Another marker, elevated triglycerides, greater than
- 21:53Speaker 2: or equal to 150. Low HDL, which is quote-unquote good cholesterol. Right.
- 21:58Speaker 2: Lower than 40 for men, lower than 50 for women.
- 22:01Speaker 2: Hypertension or high blood pressure with a systolic of 130
- 22:05Speaker 2: or greater. And a diastolic, that's the bottom number. Systolic
- 22:09Speaker 2: is the top number. You see it's like 130 over 85.
- 22:12Speaker 2: That's top number systolic, bottom number is diastolic. Probably more
- 22:15Speaker 2: information than you need, sorry.
- 22:16Speaker 1: Right.
- 22:17Speaker 2: And the last of these markers is elevated fasting glucose,
- 22:21Speaker 2: if it's over 100. Now, Sophie is 100% right. If
- 22:26Speaker 2: you have metabolic syndrome, it puts you at risk for diabetes,
- 22:31Speaker 2: coronary artery disease, heart problems, and stroke. And his assertion
- 22:37Speaker 2: that 90% of people have at least one of these
- 22:39Speaker 2: markers is actually not far off. The CDC runs this
- 22:42Speaker 2: research program called the National Health and Nutrition Examination Survey,
- 22:46Speaker 2: or NHANES. And there was an NHANES study from 2009
- 22:49Speaker 2: to 2016, and it showed that about 12 only, I
- 22:54Speaker 2: should say, only 12% of US adults were considered, quote unquote,
- 22:59Speaker 2: metabolically healthy, or basically optimal on all five of those
- 23:04Speaker 2: markers I mentioned without medication. That implies that roughly 88%
- 23:09Speaker 2: of Americans have at least one abnormal test. I'm assuming
- 23:12Speaker 2: that's where he gets this 90% number that he talks about.
- 23:15Speaker 2: And that part is, I think, true.
- 23:18Speaker 4: Hey, everyone, this is Kaveh, you know, from the future
- 23:21Speaker 4: after this recording. And I just wanted to jump in
- 23:23Speaker 4: here real quick to say that what I said was
- 23:27Speaker 4: totally correct. No, nothing factually wrong. I just hear Robert
- 23:32Speaker 4: doing this every now and then. And, you know, it
- 23:34Speaker 4: sounded fun to me. So I wanted to give it
- 23:36Speaker 4: a try. But yeah, everything I said was right. So anyways,
- 23:40Speaker 4: back to the podcast.
- 23:45Speaker 2: But the thing is, That's not how you define metabolic syndrome.
- 23:49Speaker 2: To have metabolic syndrome, you have to have three or
- 23:52Speaker 2: more of those markers. Having just one isolated marker is
- 23:56Speaker 2: probably very, very common, but it's also clinically far less meaningful.
- 24:02Speaker 2: For metabolic syndrome, you have to have at least three
- 24:04Speaker 2: of those, and it kind of just drops it to
- 24:06Speaker 2: one to start treatment. Okay. Does that make sense? Let
- 24:10Speaker 2: me stop right there. Does that make sense?
- 24:12Speaker 1: Yeah.
- 24:14Speaker 3: Sure.
- 24:14Speaker 2: Yeah.
- 24:14Speaker 1: Yeah.
- 24:15Speaker 2: These things are important to note. And I want people
- 24:18Speaker 2: to be thinking about all these things. But this concept
- 24:21Speaker 2: of saying, like, he's changing the goalpost here about definitions
- 24:26Speaker 2: that would justify treating people aggressively. And we'll talk about
- 24:29Speaker 2: why you don't want to treat everyone aggressively. But I
- 24:33Speaker 2: don't believe this justifies it. It's certainly not justifying in
- 24:37Speaker 2: a uniform approach like he applies to his patients. We
- 24:41Speaker 2: always say lifestyle modification should be the first thing you discuss.
- 24:44Speaker 2: rather than reflexively treating people with medication. I'm the one
- 24:47Speaker 2: that gets accused of being a shill for pharma, and
- 24:50Speaker 2: I'm the one that's usually saying, hey, let's hold off
- 24:52Speaker 2: on this medicine that's unproven. I don't get it.
- 24:55Speaker 3: You do say that to me often.
- 24:59Speaker 2: Yeah, I get it a lot. I'm like, what do
- 25:00Speaker 2: you think of this thing?
- 25:01Speaker 3: And you're like, no, no.
- 25:05Speaker 2: Yeah. And writing medicine is like my bag. I'm an
- 25:07Speaker 2: internal medicine doctor at heart. That's what we do. Anyways.
- 25:12Speaker 2: You should think of interventions, I feel, as a staircase
- 25:16Speaker 2: and not a switch. And the first step should always
- 25:18Speaker 2: be lifestyle modifications, if you can help it. Now, metabolic
- 25:21Speaker 2: syndrome is a risk indicator, not an absolute risk. It
- 25:24Speaker 2: doesn't account for everything, age, sex, smoking, LDL, other factors.
- 25:31Speaker 2: Aggressive lab testing that he does is a big part
- 25:34Speaker 2: of his practice and recommendations. But in these cases, it's
- 25:38Speaker 2: highly questionable about what kind of use that serves. He
- 25:42Speaker 2: focuses on these aggressive tests for blood markers that could
- 25:46Speaker 2: potentially represent heart disease. His core panel includes something called APOB,
- 25:51Speaker 2: LP little a, CRP. And then he also recommends imaging
- 25:55Speaker 2: the coronary artery calcium or the CAC scoring.
- 25:59Speaker 1: Okay.
- 25:59Speaker 2: As well as a coronary CT. I don't think other
- 26:01Speaker 2: people refer to it as CAC, but I think it's
- 26:04Speaker 2: funnier to refer to coronary artery calcium as CAC scoring.
- 26:08Speaker 1: CAC scoring.
- 26:09Speaker 2: I'm not opposed to... early focused cardiac intervention. Of all
- 26:13Speaker 2: the stuff he does, I'm the most open to hearing
- 26:15Speaker 2: about this. But a lot of what he is recommending,
- 26:18Speaker 2: a lot of this testing outruns the evidence that we
- 26:21Speaker 2: have to support its use. Some of it hasn't even
- 26:25Speaker 2: been shown to be something we could change. So for example,
- 26:28Speaker 2: these CAC scoring tests that he does, they're expensive. They
- 26:31Speaker 2: expose you to radiation and downstream test events. And there's
- 26:35Speaker 2: no trial so far that shows that doing that actually
- 26:39Speaker 2: helps you in any way or decreases cardiac events. And
- 26:43Speaker 2: whenever you do a test, you should always ask, will
- 26:46Speaker 2: the results of this test change our management? That should
- 26:50Speaker 2: always be a question you ask. And if there's nothing
- 26:52Speaker 2: different you can do, if there's nothing different it will
- 26:55Speaker 2: give you, then you have to have serious conversations. It
- 26:57Speaker 2: doesn't mean you can't do it, but it means you
- 27:00Speaker 2: can't be applying that to everybody. He also is a
- 27:05Speaker 2: proponent for early screening tests for things like colonoscopy. Which
- 27:10Speaker 2: he sees as being proactive, but I see, as a
- 27:12Speaker 2: gastroenterologist who does them, as being a bit reckless. This
- 27:16Speaker 2: is my wheelhouse, of course. And we could talk at
- 27:20Speaker 2: length about when to start colonoscopy. But for someone without
- 27:24Speaker 2: risk factors, it's 45. That's our recommended time for screening
- 27:29Speaker 2: for colon cancer. And that's lower than 50 where it
- 27:31Speaker 2: used to be. He pushes for 40.
- 27:35Speaker 1: I mean, there's a lot more younger colon cancer cases, right?
- 27:38Speaker 1: So I don't know.
- 27:39Speaker 2: Is that wrong? I could talk to you about that.
- 27:42Speaker 2: This is a fascinating topic to me. In fact, I
- 27:43Speaker 2: just released an episode about early-onset colorectal cancer, and you
- 27:47Speaker 2: are correct. There are increasing rates. Overall, the absolute risk
- 27:50Speaker 2: is still low, but there is increasing rates of why
- 27:53Speaker 2: that is. But that's why we drop it to 45. Now,
- 27:57Speaker 2: people online constantly get mad when I talk about this.
- 28:02Speaker 2: Because they'll be like, hey, I want a colonoscopy and
- 28:04Speaker 2: you doctors are not giving it to me. And I'll
- 28:05Speaker 2: be like, how old are you? And they'll be like, 30.
- 28:07Speaker 2: And I'll be like, do you have any risk factors
- 28:10Speaker 2: like family with colon cancer or family with advanced polyps
- 28:14Speaker 2: or history of inflammatory bowel disease? Or do you have any?
- 28:19Speaker 2: signs or symptoms that are concerning? And the answer is no,
- 28:21Speaker 2: they just want it. I'm like, that's not what we
- 28:23Speaker 2: want you to do. I don't want you getting colonoscopies.
- 28:26Speaker 2: I'm a guy who does colonoscopy. I get paid to
- 28:28Speaker 2: do colonoscopies, but I don't want you to get it
- 28:31Speaker 2: unless you need it.
- 28:31Speaker 1: Yeah, it's not like free for everyone, not just out
- 28:35Speaker 1: of money standpoint, but like doctors don't have unlimited time. Yeah,
- 28:38Speaker 1: I get that.
- 28:39Speaker 2: Yes, that's a big part of it. And there's more.
- 28:41Speaker 2: We'll discuss that a little more. We'll come back to it.
- 28:43Speaker 2: But what I think he is tapping into here is
- 28:47Speaker 2: is a very real dissatisfaction, disillusionment with mainstream medicine. And
- 28:54Speaker 2: I feel that. People feel like doctors, for one reason
- 28:57Speaker 2: or another, are always gatekeeping healthcare. And to be clear,
- 29:02Speaker 2: I am 100% for preventative care. This idea is not new.
- 29:06Speaker 2: We've had primary cares for this exact reason. Why he
- 29:10Speaker 2: went into surgery, I don't know. He would have been
- 29:11Speaker 2: better off had he gone to endocrinology, but, you know,
- 29:14Speaker 2: not a lot of money there. So maybe that's, I
- 29:16Speaker 2: don't want to assume that's why he did it. But
- 29:19Speaker 2: there are other things you can do to get preventative care.
- 29:24Speaker 2: And I'm, as I said, I'm a simple country doctor.
- 29:28Speaker 2: Four years of medical school, three years of internal medicine training,
- 29:32Speaker 2: a year of chief residency, three years of gastroenterology, and
- 29:35Speaker 2: a year of liver transplant fellowship under my belt. simple
- 29:39Speaker 2: country doc stuff. And I feel so much less confident
- 29:43Speaker 2: taking the giant swings he does on all these medical issues.
- 29:48Speaker 2: He has no formal training in cardiovascular disease, neurodegenerative disease, endocrinology,
- 29:53Speaker 2: or even nutritional science, yet these are the pillars of
- 29:56Speaker 2: his practice. Again, Very smart, incredible potential as a doctor.
- 30:01Speaker 2: But what he's describing as research into these fields seems
- 30:04Speaker 2: more like maybe read a couple studies and having relationships
- 30:07Speaker 2: with people that are his friends that do know more
- 30:10Speaker 2: about than him. There's something you have to consider when
- 30:13Speaker 2: you're doing all these tests, all these advanced genetic testing,
- 30:16Speaker 2: CT angiograms, these colonoscopies. There's real harms, real risks associated
- 30:22Speaker 2: with them. And we have to weigh the benefits of them.
- 30:26Speaker 2: I'm assuming you probably want to take a commercial break
- 30:29Speaker 2: before we do that.
- 30:30Speaker 1: Yeah, why not?
- 30:31Speaker 2: Yeah.
- 30:32Speaker 1: Speaking of that, ads?
- 30:35Speaker 2: Why not?
- 30:35Speaker 1: Ads. And we're back.
- 30:45Speaker 2: Yes, we are back. Now, there was a JAMA study
- 30:49Speaker 2: I want to talk about because I think this is
- 30:50Speaker 2: really funny. And funny may not be the right word.
- 30:54Speaker 2: It came out of UC Davis in 2012. It's an
- 30:56Speaker 2: old study. And what it did was this. It showed
- 30:59Speaker 2: how happy a patient was with the care they received
- 31:03Speaker 2: and how that related to their outcomes. That study showed
- 31:07Speaker 2: that the most satisfied patients had not only higher healthcare spending,
- 31:12Speaker 2: but more hospital admissions, and most strikingly, a 26% higher
- 31:18Speaker 2: risk of death compared to the least satisfied patients cool
- 31:24Speaker 2: the satisfied patients were doing worse yeah what what thoughts
- 31:29Speaker 2: do you have about why why may that be we
- 31:31Speaker 2: don't know for sure by the way the test this
- 31:33Speaker 2: study was empowered.
- 31:35Speaker 1: I guess because people like are are satisfied because they
- 31:40Speaker 1: like their doctor and they feel listened to but that
- 31:43Speaker 1: doesn't necessarily correlate to actually improving their health care outcomes
- 31:46Speaker 1: at all it's just like how people can be really
- 31:49Speaker 1: satisfied with a doctor who's selling them like snake oil
- 31:52Speaker 1: that doesn't actually cure their cancer until they fucking die.
- 31:55Speaker 1: They don't notice something's wrong. I don't know. That would
- 31:58Speaker 1: be my guess.
- 31:58Speaker 2: No, that's right. So the more satisfied patients are probably
- 32:02Speaker 2: getting more than they asked for. More tests, more side effects,
- 32:06Speaker 2: more complications. Doctors who always say yes score very well.
- 32:13Speaker 2: And sometimes saying no in medicine is really hard. But sometimes,
- 32:18Speaker 2: and not always, declining a test or medicine or antibiotic
- 32:22Speaker 2: or refusing to do a low-value scan or imaging study
- 32:25Speaker 2: may actually serve patients better. Now, this is a big, nuanced,
- 32:30Speaker 2: and difficult conversation because you have to weigh those considerations
- 32:33Speaker 2: with listening to your patients and advocating for them. And
- 32:36Speaker 2: it is not an excuse to not listen to your
- 32:38Speaker 2: patients and take their complaints seriously. I'm fully aware that
- 32:42Speaker 2: our country has a very serious problem taking patients seriously,
- 32:45Speaker 2: particularly if they are Black and or female. This is
- 32:48Speaker 2: a real problem that we have in this country. But
- 32:53Speaker 2: it's always important to keep in mind that sometimes do
- 32:56Speaker 2: no harm is the right step. Not doing the thing
- 33:00Speaker 2: is the better approach. To be totally transparent also, there
- 33:04Speaker 2: have been follow-up studies to that 2012 studies. Some have supported,
- 33:08Speaker 2: some have detracted. I feel the weight of time has
- 33:12Speaker 2: sort of borne this out, though, and it does seem
- 33:14Speaker 2: to be true. There was a 2019 Cochrane meta-analysis that
- 33:19Speaker 2: showed real dangers to over-diagnosis and treatment. It can lead
- 33:23Speaker 2: to unnecessary interventions. One test leads to another test leads
- 33:27Speaker 2: to another test, and these things have risks. Sometimes they're necessary,
- 33:30Speaker 2: sometimes they are not. And these things carry not only
- 33:33Speaker 2: real harm, but also psychological burden as well.
- 33:36Speaker 3: So.
- 33:37Speaker 2: I think largely his reason for doing this is not
- 33:40Speaker 2: bad or malicious. I think he does want to help
- 33:43Speaker 2: before a problem exists. And like I said, a lot
- 33:46Speaker 2: of his advice is reasonable stuff. And I actually kind
- 33:49Speaker 2: of like some of it. Eat less processed food, exercise,
- 33:52Speaker 2: sleep well.
- 33:52Speaker 1: Great.
- 33:54Speaker 2: But it's also paired with this really over-the-top monitoring with
- 33:58Speaker 2: intense and very pricey strategies that lack evidence. And some
- 34:03Speaker 2: of the relationships he has to these things are not
- 34:05Speaker 2: ideal at For example, he, as I mentioned, promotes continuous
- 34:10Speaker 2: glucose monitoring for people without diabetes or signs of insulin resistance.
- 34:15Speaker 1: Yeah.
- 34:16Speaker 2: Not necessary. Yes. In your medical professional experience, you would
- 34:21Speaker 2: also agree with me, and you are correct. But it's
- 34:24Speaker 2: become a big hit with the MAHA crowd, these tests.
- 34:29Speaker 2: And there's no evidence that's of any use to non-diabetic patients.
- 34:32Speaker 2: And it can lead to unnecessary dietary restrictions, anxiety, even
- 34:36Speaker 2: disordered eating. And the information, the data you get from
- 34:42Speaker 2: these continuous glucose monitorings, it's often difficult to interpret. And
- 34:46Speaker 2: getting one with an ongoing data plan is hundreds of
- 34:49Speaker 2: dollars per month.
- 34:51Speaker 3: It's expensive.
- 34:52Speaker 2: A lot of.
- 34:53Speaker 3: People that have diabetes that need these sorts of devices-
- 34:58Speaker 3: are either unable to get it or the prices are
- 35:03Speaker 3: increasing because of things like this. And I know a
- 35:07Speaker 3: specific device that you're going.
- 35:08Speaker 2: To talk about.
- 35:09Speaker 3: And I know that it is extremely difficult to at
- 35:16Speaker 3: times get that device. And I can't imagine this helps.
- 35:20Speaker 2: No, you're exactly right. That's what happens. You, the resources
- 35:24Speaker 2: are limited. Our problem in this country is not so
- 35:27Speaker 2: much that we don't have the things to help patients.
- 35:30Speaker 2: It's that we don't have access for them to get
- 35:32Speaker 2: to it.
- 35:33Speaker 1: Yeah.
- 35:34Speaker 2: And also grounding out what Sophie was alluding to there.
- 35:38Speaker 2: He was a paid advertiser for a company called Dexcom
- 35:42Speaker 2: that sells these devices. That's not ideal. It's not ideal. Um,
- 35:47Speaker 2: He has been criticized for not disclosing that very well.
- 35:51Speaker 2: I have seen him mention it, but I don't think
- 35:53Speaker 2: he did it every time. So I think it's a
- 35:55Speaker 2: valid criticism.
- 35:57Speaker 4: Sure.
- 35:57Speaker 2: By the way, that company has since said his advisory
- 36:00Speaker 2: role ended in 2021. But when this topic comes up
- 36:05Speaker 2: of concerns, hey, aren't we just creating a new tier
- 36:10Speaker 2: of medical care for just those with extreme wealth? And
- 36:13Speaker 2: that it's preventative medicine for people who are already privileged
- 36:17Speaker 2: and probably doing better. He'll downplay the cost of these
- 36:21Speaker 2: things he's ordering by correctly pointing out that the end-of-life
- 36:25Speaker 2: care is also very expensive. And that is true. A
- 36:29Speaker 2: disproportionate amount of healthcare in this country spending is at
- 36:33Speaker 2: the end of a patient's life. The cost of all
- 36:36Speaker 2: the machines and the labor and medicine in those critically
- 36:39Speaker 2: ill hospitalized patients, that adds up quickly. But both things
- 36:43Speaker 2: can be true. And nobody's saying we shouldn't practice preventative care.
- 36:47Speaker 2: But the thing is this, even if his measures do work,
- 36:50Speaker 2: which is a big if, it's still just pushing the
- 36:52Speaker 2: end-of-life care and all the money that goes into it
- 36:55Speaker 2: further down the road. So you're not saving money this way.
- 37:00Speaker 2: You're spending money on both ends. A lot of it,
- 37:03Speaker 2: a lot of health care dollars are going to go
- 37:05Speaker 2: into this on both ends. And for that reason, actually,
- 37:09Speaker 2: real quick before we move on from end-of-life care– It's
- 37:13Speaker 2: an important reason that doctors recommend having those goals of
- 37:17Speaker 2: care discussion and what you would want done if you
- 37:20Speaker 2: were to become critically ill and not be able to
- 37:23Speaker 2: weigh in. Unfortunately, when this is reasonably discussed, Republicans refer
- 37:27Speaker 2: to it as death panels, and we never get to
- 37:30Speaker 2: have this.
- 37:30Speaker 3: Right.
- 37:30Speaker 1: I remember the death panel days.
- 37:32Speaker 3: Yeah.
- 37:33Speaker 1: And then we had real death panels under a Republican. Anyway, whatever.
- 37:37Speaker 2: We've had real death panels. But having end-of-life care discussions is,
- 37:41Speaker 2: is not only important for saving money, it's also just
- 37:45Speaker 2: really important for knowing really what your loved ones want.
- 37:50Speaker 2: So I think it's... Anyways, have that discussion, folks, even
- 37:54Speaker 2: if you are healthy. You should at least be having
- 37:56Speaker 2: those discussions along the way. Now, all this, I think,
- 37:58Speaker 2: are things that you kind of learn in the actual
- 38:01Speaker 2: practice of medicine, something he missed, this do no harm.
- 38:05Speaker 3: Yeah.
- 38:06Speaker 2: The colonoscopy part, I think, is... A great example of this.
- 38:11Speaker 2: So our current guidelines have dropped to 45. He wants
- 38:13Speaker 2: it to go down even further to 40. And again,
- 38:17Speaker 2: despite how strange it might seem to some people, there
- 38:18Speaker 2: are people who want these tests done as early as possible.
- 38:22Speaker 2: But as Robert said, one part of it is we
- 38:26Speaker 2: just don't have the people to do it. I mean,
- 38:29Speaker 2: I could... do colonoscopies every day, all day for the
- 38:32Speaker 2: end of time, and I will not have scratched the
- 38:34Speaker 2: surface of the colonoscopies that need to get done. So
- 38:38Speaker 2: we're taking it away from people who need it. But
- 38:41Speaker 2: on top of that, there's risk to doing these tests.
- 38:44Speaker 2: There's actual physical risks. Bad things can happen. It's rare, thankfully.
- 38:49Speaker 2: You should get colon cancer screening. But colonoscopy does have
- 38:53Speaker 2: some risk, and it's not cheap. And again, I'm telling
- 38:55Speaker 2: you this as someone who stands to make a lot
- 38:58Speaker 2: of money off of you getting colonoscopies.
- 39:01Speaker 1: Yeah.
- 39:02Speaker 2: So take my word for this one. You're like, it's
- 39:05Speaker 2: something we have to be more mindful about.
- 39:07Speaker 1: Yeah, for sure.
- 39:10Speaker 2: He talks about some other stuff with his patients that's
- 39:13Speaker 2: overall less fun for me. He emphasizes zone two training
- 39:16Speaker 2: as optimal for mitochondrial capacity and longevity. This does contradict
- 39:21Speaker 2: some substantial evidence behind higher intensity training. Again, kind of
- 39:26Speaker 2: what he's doing here is he's cherry-picking studies that look
- 39:29Speaker 2: at observational data in elite endurance athletes. I'm not sure
- 39:33Speaker 2: how that translates. But that cherry-picking study stuff is something
- 39:37Speaker 2: that RFK Jr. does as well. And what they all
- 39:40Speaker 2: do in this sort of world.
- 39:41Speaker 1: It's a vote these days, yeah.
- 39:43Speaker 2: It's the modus operandi of our current administration. So RFK Jr.
- 39:48Speaker 2: One thing that they will all do is they will
- 39:51Speaker 2: take a little bit of data and then extrapolate it
- 39:54Speaker 2: far beyond what that data was meant to do. Something
- 39:58Speaker 2: he does this with is one of his quote-unquote horsemen.
- 40:01Speaker 2: He talks about the four horsemen of the apocalypse, and
- 40:04Speaker 2: one of them is cancer. Sorry.
- 40:08Speaker 3: That was like an audible groan.
- 40:14Speaker 4: Okay.
- 40:15Speaker 2: Sorry, I'm back. I felt that way. Again, I actually
- 40:18Speaker 2: liked parts of his book. Parts of it were, I thought,
- 40:21Speaker 2: very reasonable. But, for example, when he talks about cancer,
- 40:27Speaker 2: he points out that cancer cells require more glucose than
- 40:30Speaker 2: normal human cells. And that is true. And you'll hear
- 40:35Speaker 2: a lot of wellness people take that little bit of information.
- 40:37Speaker 1: Yeah, starve your cancer by avoiding sugar or whatever. I've
- 40:41Speaker 1: seen that a lot.
- 40:43Speaker 2: Right. They take a little bit of truth and they
- 40:45Speaker 2: make giant leaps from there regarding the nature of cancer's
- 40:48Speaker 2: formation and sugar's role in it. And it's honestly, it's
- 40:52Speaker 2: still not clear what that means, you know. Is it
- 40:54Speaker 2: the cause of the cancer, the sugar, or is it
- 40:57Speaker 2: just some interesting feature of the cancer?
- 40:59Speaker 5: Yeah.
- 41:00Speaker 2: To make jumps from a simple lab-tested fact to saying
- 41:04Speaker 2: dietary manipulations could help the growth of cancer is shaky
- 41:07Speaker 2: at best. And diet is important. I'm a huge proponent
- 41:12Speaker 2: of a healthy diet that is high in fiber. Again, fiber, folks.
- 41:15Speaker 2: I'm deep in the pocket of big fiber. But while
- 41:19Speaker 2: there is solid evidence that healthy dietary patterns can lower
- 41:22Speaker 2: your risk for things, right now... There isn't the risk
- 41:26Speaker 2: of these things he's recommending, like ketogenic diets, prolonged fasts,
- 41:30Speaker 2: caloric restrictions. There's no evidence that those things work. When
- 41:34Speaker 2: we want people to learn, when I want people to
- 41:38Speaker 2: learn about what they're eating and how it affects them,
- 41:40Speaker 2: I want it to be broad and sustainable patterns. Mostly plants,
- 41:45Speaker 2: limited red meat, limited processed meats. And I don't disagree
- 41:49Speaker 2: with limiting sugar either. I agree. For the purpose of
- 41:52Speaker 2: maximizing your cardio metabolic risks, That's well proven. I don't
- 41:56Speaker 2: find it to be a good argument in the case
- 41:58Speaker 2: of cancer. The data just isn't there yet. Or if
- 42:00Speaker 2: you're cool, you call it data. Let's talk a little
- 42:04Speaker 2: bit more about the medications. Because, again, I'm the one
- 42:07Speaker 2: that gets accused of being a pharma shill. But if
- 42:10Speaker 2: a right-wing doctor tells you to buy a year's supply
- 42:12Speaker 2: of ivermectin, you do it out there. So I'll never
- 42:16Speaker 2: understand that. Not that he's recommended ivermectin.
- 42:19Speaker 3: For the non-pharmacist. Netflix watchers, I just rolled my eyes very, very, very, very,
- 42:25Speaker 3: very dramatically.
- 42:26Speaker 2: Yeah, you're going to strain something. You got to be careful.
- 42:28Speaker 2: So he's a big fan of aggressive pharmacologic intervention using medications.
- 42:34Speaker 4: Sure he is.
- 42:35Speaker 2: Off-label. Now, I'll give one example. I could give a lot,
- 42:39Speaker 2: but there's one, and I think it's a fun one.
- 42:42Speaker 2: And there's a little nerd in me that wants to
- 42:43Speaker 2: share this story with you guys. And I think your
- 42:46Speaker 2: listeners will enjoy it. It's about a medicine that he prescribes.
- 42:50Speaker 2: for his patients called rapamycin. You might have seen it, serolimus.
- 42:55Speaker 2: And he prescribes it for longevity-enhancing purposes. And, yeah, there
- 43:01Speaker 2: is a little bit of promising preclinical data to suggest
- 43:06Speaker 2: some longevity benefits. It's still very much a hypothesis, and
- 43:10Speaker 2: there's no phase three trials to prove it. As an
- 43:14Speaker 2: interesting aside, this rapamycin is actually an antifungal And this
- 43:18Speaker 2: is fun, how it was discovered. It was discovered in
- 43:21Speaker 2: the dirt of an Easter Island volcanic crater in the
- 43:24Speaker 2: 60s in Rapa Nui. Okay.
- 43:26Speaker 1: Which I hope I'm saying right. How did they find it?
- 43:29Speaker 2: Great question. What in the world is going on here?
- 43:30Speaker 1: Were they just looking at random, just sucking up different
- 43:34Speaker 1: things that they found on the island? Does this have medical?
- 43:36Speaker 1: I don't know. How did they find it?
- 43:38Speaker 2: Great, great question. So there was this microbiologist. who was
- 43:42Speaker 2: collecting soil because they wanted to take samples, and they
- 43:45Speaker 2: wanted to figure out why the islanders who lived there
- 43:49Speaker 2: never got tetanus despite walking around with no shoes.
- 43:54Speaker 1: Cool as that. Actually, that's a really cool thing to do. Yeah,
- 43:56Speaker 1: that makes sense.
- 43:58Speaker 2: But you can imagine some Republican talking about this in
- 44:02Speaker 2: the day being like, hey, we're wasting money testing the
- 44:06Speaker 2: dirt in Rapa Nui.
- 44:08Speaker 5: Yeah.
- 44:08Speaker 2: You know, that's how it is. Yeah, that makes sense.
- 44:10Speaker 2: You never know where research is going to lead you.
- 44:13Speaker 2: And it leads you to some really amazing places. Anyways,
- 44:16Speaker 2: since discovering it, people have studied its use for all
- 44:19Speaker 2: kinds of different things. It was actually found to have
- 44:22Speaker 2: some immunosuppressive effects. So because of that, it's used for
- 44:27Speaker 2: transplant patients to alter their immune system. So if you
- 44:30Speaker 2: get a transplanted kidney, you take this medication usually to
- 44:35Speaker 2: help prevent your body from rejecting it. Now, as I mentioned,
- 44:39Speaker 2: there is some early data that suggests it can affect
- 44:42Speaker 2: lifespan of mice. Human trials have been very limited, though.
- 44:49Speaker 2: Maybe it might help improve the flu vaccine response. It's
- 44:52Speaker 2: not quite clear. People thought it could be potentially used
- 44:55Speaker 2: for weight loss, but that really didn't pan out. And
- 45:00Speaker 2: it's not shown the metabolic stuff that they expect it to,
- 45:03Speaker 2: but it's a really small example of of something that
- 45:06Speaker 2: the anti-vaccine community and something that RFK Jr. do. Extrapolating
- 45:11Speaker 2: a small truth in a small study or an animal
- 45:14Speaker 2: study to a large truth in humans, something it's not powered, meant,
- 45:19Speaker 2: or designed to do.
- 45:20Speaker 1: Right, yeah, I see a lot of this.
- 45:22Speaker 2: Yeah, it's a big stretch.
- 45:24Speaker 1: Yeah.
- 45:26Speaker 2: And I mean, it's great clickbait stuff, right? You see
- 45:28Speaker 2: an article that says like, this secret medicine discovered in
- 45:33Speaker 2: the Easter Island crater is, will expand your life. And
- 45:36Speaker 2: you're like, that's awesome. And you read it. And sometimes
- 45:39Speaker 2: if you're lucky, they'll explain that it's not that, but
- 45:42Speaker 2: it's really fun. Clickbaity stuff. It's really, it sits with
- 45:45Speaker 2: people and it's exciting. So yeah, he's.
- 45:48Speaker 3: Also a guy that like is a soundbite guy. So you're,
- 45:51Speaker 3: you know, you're going to get, you know, two minutes
- 45:53Speaker 3: of him talking on some other guy. We hates podcast
- 45:57Speaker 3: talking about how great said thing is. And it just
- 45:59Speaker 3: spreads like wildfire and, and is actually just not scientifically sound,
- 46:06Speaker 3: and you're just spreading scientific misinformation and causing harm.
- 46:11Speaker 2: That's exactly right. Yeah. Thank you. Now, because it's off-label,
- 46:16Speaker 2: there's no regulating the dose. There's no guidelines on dosing
- 46:20Speaker 2: or monitoring. Maybe there's some protective effects against aging, but
- 46:24Speaker 2: these same exact pathways... drive immunosuppression. So you can't take
- 46:29Speaker 2: these things lightly. You don't want to be immunosuppressed if
- 46:32Speaker 2: you don't need to. No. Because as the title suggests,
- 46:37Speaker 2: your immune system is being suppressed. And your immune system
- 46:40Speaker 2: is a good thing.
- 46:41Speaker 1: Yeah, I wouldn't want to take immunosuppressants as a longevity
- 46:44Speaker 1: treatment because your immune system sometimes helps you stop dying.
- 46:47Speaker 1: Like I get why it helps your longevity if you've
- 46:49Speaker 1: got like a transplant. That makes sense.
- 46:51Speaker 5: Right.
- 46:52Speaker 2: And people haven't studied its use in situations like this.
- 46:56Speaker 2: It's long-term risk of use for people who don't have
- 46:59Speaker 2: a transplant, for example. And, you know, there's some real
- 47:03Speaker 2: risk with it that we do know about. There's some
- 47:06Speaker 2: increased risk to infection, as I mentioned, the development of lymphoma,
- 47:11Speaker 2: and some metabolic problems that the whole field of longevity
- 47:14Speaker 2: is really supposedly aimed to prevent. So it's this kind
- 47:20Speaker 2: of fast and loose relationship to science and medicine that's
- 47:23Speaker 2: made him a pop culture scientist and star. He sounds
- 47:26Speaker 2: really convincing, intelligent when he talks about the stuff, especially
- 47:29Speaker 2: if it's in these short bursts. He knows how to
- 47:32Speaker 2: talk about data in a way that's even more convincing,
- 47:34Speaker 2: I feel, than Andrew Huberman. He's good at it.
- 47:37Speaker 1: Yeah.
- 47:37Speaker 3: Yeah.
- 47:38Speaker 2: And he's influencing people. He's getting the attention of everyone
- 47:41Speaker 2: in the manosphere. His approach to medicine is great for
- 47:44Speaker 2: people like RFK Jr. and anti-vaxxers. He can speak intelligently
- 47:48Speaker 2: about the data and sound authoritative, but And it can
- 47:51Speaker 2: help science wash them a little bit. He's got a
- 47:53Speaker 2: real credibility behind him. It's like when Brian Cox shows
- 47:57Speaker 2: up in Super Troopers. He gives them this whole sense
- 48:01Speaker 2: of gravitas.
- 48:02Speaker 3: Great.
- 48:02Speaker 1: I often think about Super Troopers when I'm considering the
- 48:05Speaker 1: validity of different medical opinions. Yeah.
- 48:08Speaker 2: He doesn't even need to vocally support RFK Jr. He
- 48:11Speaker 2: doesn't vocally support him. He's pretty careful about what he
- 48:14Speaker 2: says about him. But all he has to do is
- 48:16Speaker 2: give them the plausibility by not refuting them And coexisting
- 48:20Speaker 2: in the same world with them and going out of
- 48:22Speaker 2: his way to not trouble them. For example, when he's
- 48:27Speaker 2: asked about RFK Jr. 's accusation that Tylenol causes autism,
- 48:32Speaker 2: something that every doctor I know of, even ones who
- 48:35Speaker 2: don't have the same political links as me, they look
- 48:38Speaker 2: at that, they've seen it, they know anything about it,
- 48:40Speaker 2: they're like, that's kind of nonsense.
- 48:42Speaker 3: Yeah.
- 48:42Speaker 2: When he's asked about it, he describes it sort of
- 48:44Speaker 2: as a low probability event and kind of tries to
- 48:47Speaker 2: move on from that discussion.
- 48:48Speaker 3: Okay.
- 48:49Speaker 2: A low probability. Is it Pete? From all the available data,
- 48:52Speaker 2: it's a no probability event. That's the kind of thing
- 48:55Speaker 2: you have to be able to stand up. You have
- 48:57Speaker 2: to be able to take a side. And I know
- 48:59Speaker 2: people will say doctors shouldn't be political, but this isn't
- 49:02Speaker 2: even political. This is not political.
- 49:04Speaker 3: This is just due diligence.
- 49:06Speaker 1: This is just.
- 49:08Speaker 2: Yeah. Say the truth. Say the medical truth. Say the
- 49:10Speaker 2: scientific truth.
- 49:12Speaker 3: This is just the sky is blue bullshit. Yeah.
- 49:15Speaker 2: It absolutely is. So when it comes to his bastard-ish, bastardocity,
- 49:21Speaker 2: is he a medical bastard? Obviously not on the level
- 49:24Speaker 2: of Marion Sims, who we discussed before.
- 49:26Speaker 1: Right, or on RFK Jr. even. Or Dr.
- 49:29Speaker 2: Oz either, who I really don't like either.
- 49:32Speaker 5: Sure.
- 49:33Speaker 2: He's not as creepy. He's not as creepy as some
- 49:35Speaker 2: of the other longevity gurus.
- 49:38Speaker 3: I pre-laughed at that. Sorry.
- 49:40Speaker 1: No, no.
- 49:41Speaker 2: He's not as creepy.
- 49:42Speaker 3: You're not wrong.
- 49:46Speaker 1: He's not as creepy.
- 49:49Speaker 2: He's not as creepy as some of the other longevity
- 49:52Speaker 2: guys like Brian Johnson who deserves his own episode. Have
- 49:56Speaker 2: you done Brian Johnson? No. No.
- 49:59Speaker 3: I mean, he comes up every now and again.
- 50:01Speaker 1: Nah, he's not, because he's not really a bad, he's a,
- 50:03Speaker 1: we might do him because he's funny. Yeah. But he's not, like,
- 50:07Speaker 1: the thing about him that I actually do respect a
- 50:09Speaker 1: little bit is that, like, of all of the super
- 50:11Speaker 1: crazy rich maniacs out there, most of them are spending
- 50:14Speaker 1: all of their money on, like, horrible shit or really boring,
- 50:18Speaker 1: bland shit, like, I've got a bigger yacht, no, I've
- 50:20Speaker 1: got a bigger yacht, he's spending a lot of his
- 50:23Speaker 1: money on, like, dangerous self-experimentation. And that kind of mania
- 50:27Speaker 1: that I actually do respect a little bit, like, well,
- 50:29Speaker 1: you're genuinely kind of unhinged, but you're committed to being unhinged. And, like,
- 50:36Speaker 1: I kind of respect that more than, like, the way
- 50:38Speaker 1: Bezos spends his fucking money.
- 50:39Speaker 2: Yeah, no, he walks the walk. Yeah, that's a very
- 50:42Speaker 2: good point.
- 50:43Speaker 3: Yeah.
- 50:43Speaker 2: Very good point. It's the same way that, like, I mean...
- 50:46Speaker 2: I'll never totally understand deeply religious people because it's just not,
- 50:49Speaker 2: I don't have that part of me. But when somebody
- 50:52Speaker 2: believes it enough to proselytize, as annoying as that is
- 50:57Speaker 2: and how little I want to see it, there's a
- 50:59Speaker 2: part of me that's like, okay, well, they seem to
- 51:01Speaker 2: really believe it or they wouldn't care to proselytize. Like
- 51:04Speaker 2: the proselytizing, they really believe these people are going to hell,
- 51:07Speaker 2: so they want to change their minds about it because
- 51:10Speaker 2: they really believe it. So I kind of see that. Anyways,
- 51:14Speaker 2: so he's not that bad. And actually, compared to ghouls
- 51:18Speaker 2: like that, he actually kind of seems reasonable. He did
- 51:21Speaker 2: go to medical school. He didn't finish his residency, but
- 51:23Speaker 2: he did some of it. If you saw him profiled
- 51:26Speaker 2: on 60 Minutes last fall or read some of his
- 51:28Speaker 2: stuff in Scientific American, he actually comes across as a
- 51:31Speaker 2: pretty sound thinker. But this whole shtick is based on
- 51:36Speaker 2: critiques of what he calls Medicine 2.0. And all of
- 51:39Speaker 2: this is based on limited experience actually practicing Medicine 2.0.
- 51:45Speaker 2: A key point he makes in his book, which he illustrates,
- 51:48Speaker 2: is that the mortality rate per 100,000 people declined relatively
- 51:53Speaker 2: little over the course of the 20th century, if you
- 51:56Speaker 2: subtract out the deaths from the eight top infectious diseases,
- 52:01Speaker 2: implying that contemporary medicine has made scant progress against the
- 52:06Speaker 2: horsemen of things like cancer and neurodegenerative diseases. Yeah, very frustrating. Well,
- 52:12Speaker 2: first of all, yeah, one, if you take out all
- 52:15Speaker 2: these deaths that we're avoiding with, you know, treating these
- 52:18Speaker 2: infectious diseases, which is like, come on, that's pretty good.
- 52:20Speaker 2: Let's be.
- 52:21Speaker 1: Yeah, the problem is that, like, there are individual cancers, like,
- 52:24Speaker 1: up until recently, because there have been, there do seem
- 52:26Speaker 1: to be some, like, breakthroughs maybe occurring in pancreatic treatment, but, like,
- 52:30Speaker 1: there wasn't a massive amount of progress made on pancreatic
- 52:33Speaker 1: cancer compared to some other cancers up until fairly recently, but, like,
- 52:36Speaker 1: lung cancer, we've gotten... way better at dealing with.
- 52:39Speaker 2: Right.
- 52:40Speaker 1: And like, yeah, there's still some sorts of, there's still
- 52:42Speaker 1: varying sorts of like, you know, heart disease or whatever
- 52:45Speaker 1: that we don't have, but we've gotten better at like
- 52:46Speaker 1: a lot of other kinds. Like it's, it's just people are,
- 52:50Speaker 1: I think a lot of it is like, yeah, you
- 52:51Speaker 1: lose a loved one to like a disease that we
- 52:53Speaker 1: just haven't gotten a good handle on. And it's easier to,
- 52:57Speaker 1: for people in that situation to be like, Medical science
- 53:00Speaker 1: still hasn't made any progress. And it's, well, I'm sorry
- 53:03Speaker 1: you got hit by that fucking bullet, but that's not
- 53:05Speaker 1: the only thing going on, you know?
- 53:08Speaker 2: No, you're exactly right. And it is medicine 2.0, as
- 53:11Speaker 2: he would call it, that is providing those advances in
- 53:14Speaker 2: things like pancreatic cancer, which, I mean, agreed, not as
- 53:18Speaker 2: fast as it should be. And we should be pushing
- 53:21Speaker 2: this forward. But I don't think that's what medicine 3.0
- 53:24Speaker 2: really is. this, this whole thing is really not only
- 53:29Speaker 2: downplaying the role of antibiotics and vaccines, but these horsemen
- 53:33Speaker 2: he's talking about in particular cancer and Alzheimer's are diseases
- 53:37Speaker 2: of older people. The fact that he gets to write
- 53:40Speaker 2: books about how we're not treating them aggressively enough is
- 53:44Speaker 2: because our public health system had improved enough to keep
- 53:47Speaker 2: us alive long enough to get these diseases, these diseases
- 53:51Speaker 2: that are largely of older people, not completely, but largely. Um,
- 53:56Speaker 2: And this whole 3.0 thing doesn't even make sense internally.
- 54:00Speaker 2: In his book, Outlive, he discusses how immunotherapy is amazing,
- 54:04Speaker 2: and it is, but that's very much 2.0 medicine. That's
- 54:07Speaker 2: conventional medicine and research working. At the end of the day,
- 54:13Speaker 2: who has the time and the money to do these things?
- 54:17Speaker 2: We have a real problem in this country with access.
- 54:21Speaker 2: It's not enough tests, as I said. It's enough access.
- 54:24Speaker 2: And he's clearly chosen on purpose to surround himself with
- 54:27Speaker 2: only the wealthiest Americans who have the time and the
- 54:30Speaker 2: money for all the exercise he recommends, the ability to
- 54:34Speaker 2: pay for all the things, the testing, the wearable devices,
- 54:38Speaker 2: and the desire to live forever. And that's what brings
- 54:41Speaker 2: us to the last part of our conversation. But first.
- 54:44Speaker 1: Speaking of the last.
- 54:46Speaker 2: Oh, yeah.
- 54:47Speaker 1: Toby's got it. But first.
- 54:56Speaker 3: And now, Jeffrey Epstein. There we go. I know it's here.
- 55:01Speaker 3: I know it's here. I brought it up in the beginning.
- 55:03Speaker 2: Carly Rae Jepstein himself. So that's right. Where does all
- 55:07Speaker 2: this lead us to? All this Medicine 3.0, all the costs.
- 55:13Speaker 2: Who can do it? Only the wealthiest people. And that
- 55:17Speaker 2: is how our hero, Dr. Peter Attia, gets connected with
- 55:22Speaker 2: one person. Jeffrey Birmingham Epstein. I'm just kidding. I don't
- 55:26Speaker 2: think that's his middle name.
- 55:28Speaker 1: No, that was it.
- 55:29Speaker 2: Earlier this year, you might have heard CBS News announced
- 55:33Speaker 2: a whole new slate of 19 contributors as part of
- 55:36Speaker 2: the efforts. They are trying to go with Barry Weiss
- 55:40Speaker 2: to revamp the network's public image. One of the contributors
- 55:44Speaker 2: that they had hired, along with, again, Andrew Huberman, which
- 55:48Speaker 2: we could do another two-parter on, conservative Mel Ferguson- was Dr.
- 55:53Speaker 2: Peter Attia. Three days after that, the DOJ released a
- 55:59Speaker 2: chunk of Epstein files, which included over 1,700 mentions of
- 56:04Speaker 2: the name Peter Attia, and a lot of very embarrassing
- 56:09Speaker 2: and very douche-chill-inducing emails between Attia and J.E., as he
- 56:16Speaker 2: calls him, J.E., And also with Epstein's handlers, live emails
- 56:20Speaker 2: with Atiyah Epstein's handlers. Because of this, Atiyah was forced
- 56:26Speaker 2: to step down from his role at CBS. Because it
- 56:29Speaker 2: turns out, before he became this wellness influencer that he
- 56:33Speaker 2: was destined to become, with millions of followers, a very
- 56:37Speaker 2: influential book, he relied on Jeffrey Epstein's advice to help
- 56:41Speaker 2: get his concierge medical practice going. So let's get into
- 56:46Speaker 2: the Epstein files here.
- 56:48Speaker 3: Yeah.
- 56:49Speaker 2: Here we go.
- 56:51Speaker 1: Okay.
- 56:52Speaker 2: Yeah. So from Atiyah's own report, he met J.E. in 2014.
- 56:58Speaker 3: I hate every time you say that.
- 57:00Speaker 4: I know.
- 57:01Speaker 2: But like, it's just, well, it gets worse. Wait, hold on.
- 57:05Speaker 3: Yeah.
- 57:05Speaker 2: So he met Joffrey while he was raising funds for
- 57:11Speaker 2: scientific research. And interestingly, he makes a point to note
- 57:15Speaker 2: that it was facilitated, the meeting, by a female healthcare leader, Dr.
- 57:20Speaker 2: Eva Anderson Dubin. Interesting person. She was a former model,
- 57:25Speaker 2: became a doctor and philanthropist. That makes sense. Epstein clearly
- 57:30Speaker 2: kept ties across academia. They remained in contact over the years,
- 57:34Speaker 2: exchanging emails. They exchanged advice. Eventually, Atiyah lets Epstein know
- 57:40Speaker 2: that he's looking for someone to help run his office.
- 57:42Speaker 2: I have this office, it's concierge practice, but I need
- 57:45Speaker 2: a patient care coordinator, someone to like walk them through
- 57:48Speaker 2: the whole thing, someone that's going to make the experience
- 57:51Speaker 2: really enjoyable for them. And he's asking for his help
- 57:54Speaker 2: in finding him or her. Epstein invited Atiyah to his
- 57:59Speaker 2: Upper East Side mansion and introduced him to a foreign-born
- 58:03Speaker 2: model Okay. Yeah. You might see where this is starting
- 58:08Speaker 2: to head.
- 58:08Speaker 1: Oh, this is 2014, right?
- 58:12Speaker 2: Yes, 2014.
- 58:12Speaker 1: Okay, so he had been convicted and everybody knew.
- 58:15Speaker 2: Oh, yeah. That was 2008, if I remember correctly.
- 58:18Speaker 1: Just always really want to highlight when somebody befriends Jeffrey
- 58:22Speaker 1: after that. Yeah.
- 58:23Speaker 2: Yes. Oh, yeah. We're going to get to whether or
- 58:25Speaker 2: not he had a sense of what was going on
- 58:28Speaker 2: or not here, too. I think there's some telltale signs
- 58:31Speaker 2: in his emails. So, Atiyah, is introduced to this foreign-born model.
- 58:38Speaker 2: They exchange emails. And in other emails, it's clear that
- 58:42Speaker 2: Atiyah has invited her to a hangout with some other
- 58:46Speaker 2: potential candidates, other people at Swanky Bar in Midtown. I
- 58:51Speaker 2: think she will be loyal, Epstein writes to Atiyah in
- 58:55Speaker 2: an email. Turns out this woman was also a victim.
- 58:58Speaker 2: Her name is redacted, but she was one of Epstein's victims.
- 59:03Speaker 2: And from Atiyah's spokesperson, they say that this person never
- 59:07Speaker 2: ended up working for them. After all, they said... that
- 59:10Speaker 2: for some other reason, they went with somebody else. That
- 59:13Speaker 2: wasn't even the reason he was at Jeffrey Epstein's apartment.
- 59:17Speaker 2: But Politico reports that it was visa issues that were
- 59:20Speaker 2: the problem. And you can see this in the emails.
- 59:22Speaker 2: The emails are like, hey, she's great, but there's this
- 59:26Speaker 2: visa issue, and I don't think we can be able
- 59:28Speaker 2: to get past that. And this is the kind of
- 59:30Speaker 2: thing you see a lot in these emails, Atiyah relying
- 59:33Speaker 2: on Epstein for referrals and providing him with health advice
- 59:37Speaker 2: and testing. He downplays their relationship. He admits to hanging
- 59:40Speaker 2: out about 10 times after that until Jeffrey Epstein's arrest.
- 59:46Speaker 2: He says the hangouts happened at Jeffrey Epstein's home, although
- 59:49Speaker 2: from emails, he did have interest in going to the island.
- 59:52Speaker 2: And there was even a plan to go to the
- 59:54Speaker 2: New Mexico ranch that Epstein owned, but there was no
- 59:57Speaker 2: evidence that actually proves that.
- 59:58Speaker 1: He actually did that. The Zorro Ranch.
- 1:00:00Speaker 2: Is that what it's called?
- 1:00:01Speaker 1: Yeah, the Zorro Ranch.
- 1:00:02Speaker 2: Yeah.
- 1:00:02Speaker 1: Oh, my God.
- 1:00:04Speaker 2: So he definitely did stay at one of Epstein's apartments
- 1:00:06Speaker 2: in New York for some time period. Cool.
- 1:00:09Speaker 3: Yeah.
- 1:00:10Speaker 2: He used Epstein to help fill out his clientele as well.
- 1:00:14Speaker 2: That's really where I think Epstein came on big.
- 1:00:17Speaker 4: Great.
- 1:00:18Speaker 1: Yeah, because he can connect him to other rich guys
- 1:00:19Speaker 1: who are interested in longevity stuff.
- 1:00:21Speaker 2: That's exactly right. And it looks like he's giving him medication.
- 1:00:24Speaker 2: He's probably giving him metformin, which is another diabetes medication,
- 1:00:27Speaker 2: which I don't.
- 1:00:27Speaker 1: Think Epstein had. It's very popular for life extension folks.
- 1:00:31Speaker 2: Right, yeah. In return, he provides medical care and advice.
- 1:00:36Speaker 2: And to quote Atiyah later, he says, to be clear,
- 1:00:39Speaker 2: I never witnessed illegal behavior and never saw anyone who
- 1:00:43Speaker 2: appeared underage in his presence. But, To also be clear.
- 1:00:47Speaker 1: Appeared doing a lot of work. That is a very,
- 1:00:51Speaker 1: very strong piece of verbiage there. There's a lot weighted
- 1:00:56Speaker 1: on that.
- 1:00:57Speaker 2: Yes, exactly right.
- 1:00:58Speaker 1: Disgusting.
- 1:01:00Speaker 2: It's not ideal. No, no, no. No, men are terrible.
- 1:01:04Speaker 2: I don't think you're going to find Robert and I
- 1:01:05Speaker 2: defending men in general. No.
- 1:01:08Speaker 1: I'm being very specific about who I'm attacking here.
- 1:01:13Speaker 2: Okay. Also... To be clear, it was not a mystery
- 1:01:18Speaker 2: at this point who Epstein was. As you mentioned, he
- 1:01:21Speaker 2: already had a record and a reputation well known, and
- 1:01:25Speaker 2: you can even tell from these emails that Atiyah knows
- 1:01:28Speaker 2: his friend is infamous. I reviewed as many of these
- 1:01:32Speaker 2: emails as I could tolerate, and there's a couple lines
- 1:01:34Speaker 2: I want to read through some of these for you
- 1:01:36Speaker 2: guys that I think stand out. 2015, an email thread
- 1:01:40Speaker 2: from Atiyah with a redacted photo. and the subject line,
- 1:01:45Speaker 2: got a fresh shipment. Not clear what Atiyah was referring
- 1:01:49Speaker 2: to there. Hold on. It's not clear what Atiyah's referring
- 1:01:53Speaker 2: to there. He said later it was the medication metformin,
- 1:01:56Speaker 2: but that kind of weird. But Epstein responds with an
- 1:02:00Speaker 2: email that says, me too, with an attached photo, but
- 1:02:04Speaker 2: the attached photo is redacted.
- 1:02:07Speaker 1: I got some theories.
- 1:02:08Speaker 2: Well, Atiyah's response, let me tell you first before you
- 1:02:11Speaker 2: tell me your theories, Atiyah's response was, Please tell me
- 1:02:15Speaker 2: you found that picture online. Dot, dot, dot. Bastard. Cool. Yeah. Yeah. Fuckers.
- 1:02:23Speaker 1: Not a lot. We're not exactly. We're not exactly connecting. Like,
- 1:02:27Speaker 1: this isn't like a crazy board situation where we have to, like,
- 1:02:30Speaker 1: draw pictures with, like, twine. It's pretty obvious what's happening here. Yeah.
- 1:02:38Speaker 2: Epstein's response was, afraid not. He just. He's so ghoulish,
- 1:02:44Speaker 2: even in his emails.
- 1:02:46Speaker 1: What always takes me is not Epstein's ghoulishness, because he's Epstein.
- 1:02:50Speaker 1: It's the degree to which you can tell there's so
- 1:02:53Speaker 1: many of these guys that all cool is to them
- 1:02:56Speaker 1: is having access to frighteningly young women. Like, that's cool.
- 1:03:01Speaker 1: That's what makes you have, like, an enviable life is
- 1:03:03Speaker 1: the young girls around you.
- 1:03:07Speaker 2: Cool. And to be clear, Atiyah's not the only doctor
- 1:03:11Speaker 2: in these files. providing medical care or doing something for, for,
- 1:03:18Speaker 2: for Epstein. And that bums me out so much. There's
- 1:03:22Speaker 2: like one normal Norman Finkelstein to every like 20 other
- 1:03:27Speaker 2: dudes trying to like get in on Epstein in Epstein's world.
- 1:03:32Speaker 2: You know, Norman Finkelstein was invited to go to his, uh,
- 1:03:35Speaker 2: he's the Columbia professor. I don't know if you know
- 1:03:37Speaker 2: who he is. Cool dude. Um, Anyways, he was invited
- 1:03:41Speaker 2: by another academic colleague, and he was like, no, and
- 1:03:44Speaker 2: if I ever see you bringing your daughter to hang
- 1:03:47Speaker 2: out with Epstein, I'll throttle you. There are some cool
- 1:03:51Speaker 2: dudes out there. But for the most part, it's just
- 1:03:54Speaker 2: dudes like this who just want to be close to power.
- 1:03:58Speaker 2: They want to be close to it. They want to
- 1:03:59Speaker 2: suckle at the teat of these rich and powerful people.
- 1:04:03Speaker 2: And doctors are no exception, and that really... bums me out.
- 1:04:08Speaker 2: And not just because we took a stupid oath, but because, like,
- 1:04:10Speaker 2: it's not our job. And it leads to more... We'll
- 1:04:15Speaker 2: get to that. I got something to deal with. Anyways, okay.
- 1:04:18Speaker 2: So anyways, Epstein said, afraid not. So, you know, in
- 1:04:24Speaker 2: defense of Etia, he said it was a picture of
- 1:04:28Speaker 2: an adult woman. Now, I don't think that makes a
- 1:04:31Speaker 2: lot of sense, because if it was a picture of
- 1:04:33Speaker 2: an adult woman... why would he say, please tell me
- 1:04:36Speaker 2: you found that picture online, dot, dot, dot, bastard? Yeah.
- 1:04:40Speaker 1: I mean, I guess because he's like, theoretically, maybe just
- 1:04:43Speaker 1: some hot adult lady that he's like, oh, please tell
- 1:04:45Speaker 1: me that's not someone you're in front of right now
- 1:04:48Speaker 1: because it's so cool that you get to fuck her, right? Like,
- 1:04:51Speaker 1: that would be the defensive thing, knowing what we know
- 1:04:53Speaker 1: about Jeffrey. My assumption isn't that she's of age.
- 1:04:56Speaker 2: I don't think so either. And I also doesn't, I mean,
- 1:04:59Speaker 2: if my buddy was like, hey, this is this hot
- 1:05:01Speaker 2: chick that I'm hooking up with, and she's of age,
- 1:05:05Speaker 2: and it seems like normal. I don't think I'd be.
- 1:05:07Speaker 1: If he just sends me a picture of her sight unseen,
- 1:05:10Speaker 1: that's also upsetting.
- 1:05:11Speaker 2: That's pretty weird.
- 1:05:12Speaker 1: But also, I mean, here's what I'll say. There were guys,
- 1:05:16Speaker 1: and I kind of suspect Bill Clinton was one of them,
- 1:05:17Speaker 1: who Jeffrey would have played them with women, but would
- 1:05:20Speaker 1: have played them with adult women, because he didn't just
- 1:05:22Speaker 1: automatically send someone underage. That's not what every creepy guy prefers.
- 1:05:26Speaker 1: There's some creepy men who prefer to have sex with, like, 20-year-olds, right?
- 1:05:29Speaker 2: Right. Like.
- 1:05:31Speaker 1: that are provided to them by a service or whatever.
- 1:05:33Speaker 1: So that's not impossible. But even if, even if the,
- 1:05:37Speaker 1: he's playing you with adult women, you know what Jeffrey,
- 1:05:40Speaker 1: you know, he got arrested for trafficking children. You know
- 1:05:44Speaker 1: what he's doing to other guys, just because your taste
- 1:05:47Speaker 1: is like not a felony. Doesn't mean that you're not
- 1:05:50Speaker 1: enabling and supporting a guy who's trafficking children as a pen, right?
- 1:05:55Speaker 2: Even if you never saw it, You know what was happening.
- 1:05:59Speaker 2: You know.
- 1:06:00Speaker 1: And I don't believe that never saw it.
- 1:06:03Speaker 2: Right.
- 1:06:04Speaker 1: I think I think Jeffrey brought out a smorgasbord, you know,
- 1:06:07Speaker 1: for the rich, powerful men. And some of them were adults.
- 1:06:09Speaker 1: Some of them weren't. But the guys, they know what's
- 1:06:12Speaker 1: happening and they often see what's happening, even if their
- 1:06:16Speaker 1: tastes are not in that direction.
- 1:06:18Speaker 2: Yeah.
- 1:06:18Speaker 3: Yeah.
- 1:06:20Speaker 2: So another email from 2016, Atiyah tells Epstein that he would, quote,
- 1:06:25Speaker 2: love to add five years or more to your life,
- 1:06:27Speaker 2: even if the only reason to do so is to
- 1:06:30Speaker 2: have more sex. It's so gross.
- 1:06:33Speaker 1: Cool stuff, Peter.
- 1:06:35Speaker 2: It's so gross. Nice.
- 1:06:36Speaker 1: Yeah, disgusting.
- 1:06:38Speaker 2: I'm going to read this next one also, but I
- 1:06:41Speaker 2: want you to take a drink of your water while
- 1:06:42Speaker 2: you do it.
- 1:06:44Speaker 1: Okay.
- 1:06:44Speaker 2: Okay. In a related exchange, he asked J.E., have you
- 1:06:48Speaker 2: decided if you're interested in living longer? Solely for the ladies,
- 1:06:51Speaker 2: of course. Spit take.
- 1:06:53Speaker 1: I was going to do a spit take, but I
- 1:06:54Speaker 1: don't want to actually like.
- 1:06:55Speaker 2: I don't want to have to then clean up after that.
- 1:06:58Speaker 1: I've got like vegetable powder in my water.
- 1:07:01Speaker 2: I don't want you to ask me about eating vegetable powder. Okay,
- 1:07:03Speaker 2: another email. And this one's a big one. The biggest
- 1:07:07Speaker 2: problem with becoming friends with you, the life you lead
- 1:07:11Speaker 2: is so outrageous, and yet I can't tell a soul.
- 1:07:14Speaker 2: Why not, Pete? Why can't you tell a soul, Pete?
- 1:07:16Speaker 1: Yeah, because of the felonies. Because of the felonies.
- 1:07:20Speaker 2: Listen, he knew the guy was a dirtbag, but I'll
- 1:07:23Speaker 2: say this. I've become friends from doing this podcast with
- 1:07:26Speaker 2: a couple of famous people. I tell everyone about it
- 1:07:30Speaker 2: because they're not ghouls, Pete. They're not ghouls. If you
- 1:07:34Speaker 2: hang out with people that aren't terrible, you can tell people.
- 1:07:39Speaker 1: Yeah. It's this idea that like what cool is and
- 1:07:42Speaker 1: like the real, like the only kind of life that's
- 1:07:44Speaker 1: really worth bragging about is one in which you just
- 1:07:46Speaker 1: have constant, very young women or girls around you all
- 1:07:49Speaker 1: the time. And it's all about like, it's, it's a very,
- 1:07:52Speaker 1: wasn't cool enough in a high school and never got
- 1:07:54Speaker 1: over it attitude as opposed to like, I don't know.
- 1:07:57Speaker 1: Like when I think of the people I know who
- 1:08:00Speaker 1: are like really cool and who I like tell people about,
- 1:08:02Speaker 1: cause their lifestyle is so amazing. It's folks who like,
- 1:08:06Speaker 1: have hobbies and do stuff like, you know, they participate
- 1:08:09Speaker 1: in like fucking incredible races or they like build things.
- 1:08:12Speaker 1: They make like weird custom cars or motorcycles, uh, or they,
- 1:08:16Speaker 1: they engage in like incredible feats of athleticism. You know,
- 1:08:20Speaker 1: they build things, they into 3d printing or like they
- 1:08:23Speaker 1: have skills and they make stuff and they, I don't know,
- 1:08:26Speaker 1: that all takes money, but it's, it's actually impressive as
- 1:08:29Speaker 1: opposed to just like, Oh yeah, you're just hanging out
- 1:08:31Speaker 1: a bunch of around a bunch of like really young
- 1:08:33Speaker 1: women who you're probably applying with money.
- 1:08:35Speaker 2: Cool yeah okay um another email that struck me it
- 1:08:39Speaker 2: was him pleading with epstein's handlers to basically help arrange
- 1:08:43Speaker 2: a play date with him i go into je withdrawals
- 1:08:45Speaker 2: when i don't see him uh famously there is the
- 1:08:48Speaker 2: email from a tia to epstein discussing the issue of
- 1:08:51Speaker 2: cunnilingus that i brought up in the very beginning of
- 1:08:53Speaker 2: the first podcast and i apologize i'm sorry Pussy is
- 1:08:59Speaker 2: indeed low carb. Still awaiting results on gluten, though. Okay.
- 1:09:04Speaker 2: Now I'm going to say something that's very, very controversial here.
- 1:09:07Speaker 1: Okay?
- 1:09:08Speaker 2: And I apologize in advance. Feel free to cut. But
- 1:09:12Speaker 2: in a vacuum, this conversation I don't think is completely
- 1:09:16Speaker 2: terrible for a couple reasons. One, It would at least
- 1:09:20Speaker 2: suggest they're attempting to provide some pleasure. But that is
- 1:09:24Speaker 2: something that I encourage men to do in general with
- 1:09:26Speaker 2: their partners because I think there's a potential health benefit
- 1:09:30Speaker 2: in terms of probiotics for men to get. And more
- 1:09:32Speaker 2: men should be doing it if their partners want it.
- 1:09:35Speaker 2: But I don't know if there are benefits because nobody
- 1:09:36Speaker 2: will ever fund that study. But the point is, if
- 1:09:39Speaker 2: one of the two people in this conversation weren't the
- 1:09:41Speaker 2: worst people in history, this could be a genuinely interesting
- 1:09:46Speaker 2: scientific question. The nerd in me has curiosity.
- 1:09:50Speaker 1: If, if Jeffrey, if someone's talking about like giving a
- 1:09:52Speaker 1: massage to like a partner, that's perfectly fine. If it's
- 1:09:56Speaker 1: Jeffrey Epstein, it's not because that partner is probably not
- 1:09:58Speaker 1: an adult, right? Like that's the thing.
- 1:10:01Speaker 2: Yes.
- 1:10:01Speaker 1: That's the issue. I think is that you just have
- 1:10:04Speaker 1: no idea.
- 1:10:05Speaker 2: It's very gross. I agree. It's very, but I mean,
- 1:10:07Speaker 2: as a scientist, there's a part of me that has,
- 1:10:11Speaker 2: has questions. Um, but let's, let's move past that. Um,
- 1:10:16Speaker 2: There's one other thing that his emails shed light on.
- 1:10:19Speaker 2: It's something that was dug up afterwards. I'm not sure
- 1:10:21Speaker 2: if it got enough attention. In his book, he shares
- 1:10:25Speaker 2: that in July of 2017, while he was in New York,
- 1:10:28Speaker 2: his one-month-old son back in California almost died. Has to
- 1:10:32Speaker 2: be resuscitated by his wife, who's a nurse. And for
- 1:10:35Speaker 2: four days, his wife is begging him to come back home.
- 1:10:39Speaker 2: She had to perform the resuscitation herself. The child is
- 1:10:41Speaker 2: in the ICU. She needs him back home. And he
- 1:10:45Speaker 2: didn't because he felt his work was too important. That's
- 1:10:48Speaker 2: his own admission. Now, he will say that this was
- 1:10:51Speaker 2: a mistake. He frames it as having deep disgust with
- 1:10:54Speaker 2: himself for doing that. He's like, I thought my work
- 1:10:57Speaker 2: was so important, I had to stay to do my work.
- 1:11:00Speaker 2: But here's the thing. In his book, he shares the
- 1:11:03Speaker 2: date being July 11th. And when you go through the files,
- 1:11:05Speaker 2: the Epstein files, he has an email exchange on July
- 1:11:08Speaker 2: 13th to Epstein, where basically he's planning to meet him.
- 1:11:12Speaker 2: And he's like, yeah, I'll meet you wherever you want. Like,
- 1:11:15Speaker 2: so during this time while this kid is in the ICU,
- 1:11:19Speaker 2: he is still there doing important work, quote unquote, but
- 1:11:22Speaker 2: really it's to try and hang out with Epstein. And
- 1:11:25Speaker 2: that is rough out of all the things. That's a really,
- 1:11:28Speaker 2: that's a tough one. And I will say this. I
- 1:11:32Speaker 2: think if anything gives him shame, it is that. That's
- 1:11:36Speaker 2: the only good news is that he probably does feel
- 1:11:38Speaker 2: terrible about that.
- 1:11:39Speaker 5: No.
- 1:11:40Speaker 1: Yeah.
- 1:11:41Speaker 2: Along with the CBS fallout, he also parted ways with
- 1:11:44Speaker 2: protein bar company David and powdered supplement maker AG1 or
- 1:11:48Speaker 2: Athletic Greens. And he's currently in a lawsuit with wearable
- 1:11:51Speaker 2: medical tracker Aura, the Aura ring, after they distanced themselves
- 1:11:55Speaker 2: from him. They sound kind of like a sketchy company themselves.
- 1:11:58Speaker 1: But I don't know.
- 1:12:00Speaker 2: The thing about this, this is really a cautionary tale,
- 1:12:03Speaker 2: I think, for all doctors. It's the cautions of interacting
- 1:12:06Speaker 2: with people with fame and power. Doctors, as I mentioned,
- 1:12:10Speaker 2: are people pleasers at heart. And just like anyone else,
- 1:12:12Speaker 2: we can be drawn to the appeals of the rich
- 1:12:15Speaker 2: and famous. And doctors can find themselves doing things to
- 1:12:19Speaker 2: and for these people that they wouldn't do for other patients.
- 1:12:22Speaker 2: And like that 2012 study, this is not always a
- 1:12:25Speaker 2: service to people. Nope. Patient satisfaction doesn't always correlate with
- 1:12:30Speaker 2: good outcomes. They want to be liked by these individuals.
- 1:12:32Speaker 2: They want to be seen as useful patients. And that
- 1:12:34Speaker 2: can land the doctor, and more importantly, the patient, in
- 1:12:38Speaker 2: serious trouble. Look at Michael Jackson's doctor, Matthew Perry's, Joan Rivers.
- 1:12:43Speaker 2: These are all examples of when doctors probably overstepped the
- 1:12:46Speaker 2: bounds of what they should have done, in part at
- 1:12:49Speaker 2: least because they were dealing with a famous and rich person. So,
- 1:12:53Speaker 2: my closing thoughts. Again, there's a lot of what he
- 1:12:57Speaker 2: does that is not bad.
- 1:12:59Speaker 1: Uh-uh.
- 1:13:01Speaker 2: I'm well aware, as I said, that he is not
- 1:13:03Speaker 2: the worst person, one of the least bad people we've
- 1:13:05Speaker 2: ever done on the show. And I still hold out.
- 1:13:07Speaker 1: I don't know.
- 1:13:08Speaker 3: Hung out with Epstein.
- 1:13:09Speaker 1: The Epstein stuff really changes my opinion on that a bit.
- 1:13:12Speaker 2: Yeah. I still hold out hope for redemption arc as
- 1:13:15Speaker 2: I do for everyone. I don't know why I do that,
- 1:13:17Speaker 2: but I can't help but do that. But. What it does,
- 1:13:21Speaker 2: it says a lot about the practice of medicine in
- 1:13:24Speaker 2: this country and how it is moving towards becoming something
- 1:13:27Speaker 2: even more economically inaccessible and unequal. It says something about
- 1:13:30Speaker 2: the common pitfalls doctors make once they become public figures
- 1:13:35Speaker 2: and what can happen when influence outweighs the actual science,
- 1:13:41Speaker 2: becomes more important than the actual science. I think he's
- 1:13:44Speaker 2: sort of the missing link between the dangerous maha pseudoscience
- 1:13:48Speaker 2: practitioners and the more mainstream, but kind of also problematic
- 1:13:52Speaker 2: healthcare leaders like recent FDA commissioner, Marty Macari, who he
- 1:13:57Speaker 2: claims is his close personal friend. He's not a bastard
- 1:14:00Speaker 2: because he's malicious. He's because it's consequential. He's part of
- 1:14:05Speaker 2: this push that's making medicine. I think he's a bastard.
- 1:14:09Speaker 3: I'm just going to.
- 1:14:11Speaker 2: Say it. I will say this. Like, I feel comfortable
- 1:14:14Speaker 2: when he talks about certain things. He talks about strength training. Fine.
- 1:14:18Speaker 2: Do it. Um, And I do want people listening to
- 1:14:22Speaker 2: these things and learning about metabolic syndrome and learning what
- 1:14:24Speaker 2: it is. I also don't want them being so hyper-focused
- 1:14:27Speaker 2: on it. I think... We face bigger problems when he
- 1:14:30Speaker 2: faces into areas where he doesn't have expertise. For example,
- 1:14:33Speaker 2: we talked about colon cancer and I know what's right there.
- 1:14:36Speaker 2: Then it sounds really silly to me. And I'm like,
- 1:14:38Speaker 2: you just can't be an expert in all things, which
- 1:14:41Speaker 2: is something that we have to address and grapple with
- 1:14:44Speaker 2: as medical podcasters. And this is something I have to
- 1:14:46Speaker 2: wrestle with all the time, which is how do we
- 1:14:50Speaker 2: do what we do and not fall into these common mistakes?
- 1:14:54Speaker 2: And I try hard, but I don't know, maybe I'm
- 1:14:56Speaker 2: not perfect either about this. I don't consider myself a
- 1:14:58Speaker 2: medical influencer like he is, but it's always concerning to
- 1:15:03Speaker 2: me if I'm overstepping my expertise or my bounds. So
- 1:15:07Speaker 2: having the air of authority but without the same responsibility
- 1:15:11Speaker 2: and guardrails of real medical practice is a concern for
- 1:15:15Speaker 2: all physician podcasters, myself included, and is a concern here
- 1:15:19Speaker 2: with him. It's something we should all be aware of.
- 1:15:20Speaker 3: Yeah.
- 1:15:22Speaker 2: But the long and short of it is I think
- 1:15:24Speaker 2: he is a part of this push that is making
- 1:15:26Speaker 2: medicine less scientific and it's making medicine less accessible. And
- 1:15:30Speaker 2: it really worries me and concerns me. And that is
- 1:15:33Speaker 2: my shtick on Dr. Peter Attia.
- 1:15:38Speaker 1: Well, thank you.
- 1:15:39Speaker 2: Thanks, Kaveh.
- 1:15:40Speaker 1: Yeah, bastard ends of things. You want to plug things
- 1:15:43Speaker 1: before we roll out here?
- 1:15:45Speaker 2: I certainly do. I want to plug my podcast, The
- 1:15:47Speaker 2: House of Pod. It is a fun-ish medical podcast. We
- 1:15:51Speaker 2: look at science. We look at wellness grifters and make
- 1:15:53Speaker 2: fun of them. And we talk about what RFK Jr.
- 1:15:55Speaker 2: is doing to our terrible country. But even more than that,
- 1:15:57Speaker 2: I want you to listen to my brand new podcast
- 1:16:00Speaker 2: that I'm very excited about called Persian of Interest. It's
- 1:16:03Speaker 2: about Persian contributions to art, music, philosophy, science, a lot
- 1:16:08Speaker 2: of the fun stories that we've been written out of
- 1:16:11Speaker 2: or minimized in. And we're going to cover a lot
- 1:16:13Speaker 2: of great topics with a lot of great guests. It's
- 1:16:15Speaker 2: going to be a really fun time. Please check it out. Bye. Bye.
- 1:16:20Speaker 1: Bye.
- 1:16:24Speaker 3: Behind the Bastards is a production of Cool Zone Media.
- 1:16:27Speaker 3: For more from Cool Zone Media, visit our website, coolzonemedia.com.
- 1:16:31Speaker 3: Or check us out on the iHeartRadio app, Apple Podcasts,
- 1:16:34Speaker 3: or wherever you get your podcasts. Full video episodes of
- 1:16:37Speaker 3: Behind the Bastards are now streaming on Netflix, dropping every
- 1:16:40Speaker 3: Tuesday and Thursday. Hit Remind Me on Netflix so you
- 1:16:43Speaker 3: don't miss an episode. For clips and our older episode catalog,
- 1:16:46Speaker 3: continue to subscribe to our YouTube channel, youtube.com slash at
- 1:16:50Speaker 3: Behind the Bastards. We love about 40% of you, statistically speaking.